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Abstract 
Traumatic brain injury (TBI) is considered a silent epidemic affecting millions of people 
worldwide.  Mild TBI (mTBI) is especially a concern as it is the most prevalent form of TBI 
suffered by individuals who participate in high-contact sports or even the military.  Recently, 
clinicians have emphasized assessing concentration of proteins within biological fluids that can 
serve as surrogate biomarkers of TBI.  Many proteins have been investigated, but none has 
examined the cellular prion protein (PrPC), which is expressed abundantly along the extracellular 
domain on plasma membrane lipid rafts within the central nervous system, and is associated with 
various important functions.  Furthermore, there is mounting evidence that PrPC release from the 
CNS may be indicative of neurodegeneration, neurotoxicity, and dysregulation of normal 
signaling pathways, all of which are staples of TBI.  Given PrPC’s extracellular attachment, it is 
possible that mechanical stretching and shearing forces due to head impact, acceleratory forces to 
the head, or even oscillating blast exposure can result in PrPC dislodgement allowing it to collect 
within the systemic circulation.  Moreover, sustained secondary injury mechanisms such as 
neuroinflammation and oxidative stress for example are known to upregulate PrPC and even 
cause its release potentially leading to prolonged elevation of plasma PrPC concentration 
following TBI.  
Using an advanced blast simulation apparatus, anesthetized adult Sprague-Dawley rats 
were subjected to head-only exposure to helium gas-driven primary blast wave of varying 
intensities.  Plasma samples were collected 24 hours following blast exposure and assayed for 
PrPC analyte concentration as well as being used for comparative immunoblotting against other 
TBI biomarkers.  Furthermore, pre-clinical human plasma samples were collected from athletes 
following concussion to be analyzed for PrPC concentration against baseline samples collected 
during the offseason as well as non-athlete controls.  Plasma PrPC concentration values were 
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determined by sensitive quantification using a PrPC-specific enzyme linked immunosorbent 
assay (ELISA) and found that PrPC levels are increased following blast exposure, and partly 
mitigated by protective head covering.  Likewise, human samples show that PrPC plasma 
concentration shows an increased trend following concussion and are significantly elevated when 
compared to overall normal values.  The results demonstrated within this thesis demonstrate that 
PrPC is a potentially novel biomarker for detection of TBI and further alludes towards the 
protein’s involvement in the complex TBI pathology. 
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Introduction 
Sport-related concussions and blast-induced traumatic brain injury (b(TBI) are very 
similar, and in most cases are considered as mild TBI (mTBI).  Sports are one of the leading 
causes of mTBI among children and young adults.  While military service members abroad are 
highly at risk for blast exposure.  This especially pertains to recent military conflicts in the 
Middle East where the use of explosive munitions and improvised devices have been the 
hallmark of indigenous militant forces.  Despite several clinical symptoms and manifestations, it 
is believed that the majority of sports-related mTBI and bTBI are underreported by the injured 
and/or overlooked by clinicians.  These undiagnosed individuals are at further risk of repeat 
injury or exposure without proper precautionary measures taken, which can be particularly 
disastrous and increases the likelihood of developing long-term neurodegeneration.  Current 
standards of care rely on cognitive testing and diagnostic medical imaging techniques, but many 
injury cases can be undetected due to lack of distinguishing signs.  It is thus necessary to have 
access to more reliable and easy to use quantitative diagnostic measurements to identify those 
suspected of sustaining TBI.  Protein biomarkers in biological fluids provide clinicians a 
surrogate means to determine brain injury as well as the degree of injury and potential outcome.  
Various blood plasma proteins have been investigated recently, with some showing promise and 
others remaining controversial amongst investigators.  However, it is important to continue 
searching for protein biomarkers of TBI not only to provide a quicker, objective, and less 
invasive method of diagnosis, but also to divulge the complex pathology of TBI, which is still 
not fully understood.  A protein located within the central nervous system (CNS) involved in 
many important neuronal functions is PrPC, which can potentially be a novel marker of TBI. 
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The cellular prion protein (PrPC) is a loosely associated lipid raft protein ubiquitously 
expressed throughout the body, but is primarily located within the CNS.  PrPC has been linked to 
several important physiological functions that suggest the protein is involved in normal CNS 
function as well as being neuroprotective.  Given PrPC’s loose attachment via its glycosyl-
phosphatidyl-inositol (GPI) anchor along the extracellular surface of the plasma membrane, it is 
possible that given sufficient mechanical force or shear stress as a result of mild and blast TBI, 
PrPC may dislodge off the neuronal lipid rafts, eventually ending up in circulation.  Acute TBI 
primary injury mechanisms such as contusion, axonal shearing, diffuse neuronal injury and cell 
death, damaged blood vessels leading to hemorrhage and ischemia, and increased CNS 
permeability due to damaged meninges and blood brain barrier (BBB) can all contribute towards 
increased neuronal PrPC levels within the blood.  Furthermore, prolonged secondary injury 
mechanisms following TBI, typically involving biochemical cascades triggered from the primary 
injury, such as neuroinflammation, oxidative stress, neurotoxicity, apoptosis, as well as central 
immune response have been shown to increase PrPC expression or release from the CNS.  PrPC 
levels in biological fluids such as cerebral spinal fluid (CSF) and plasma have been previously 
used as a potential biomarker for certain pathological conditions including prion diseases 
(Picard-Hagen, et al. 2006), Alzheimer’s disease (Volkel, et al. 2001), ischemic stroke (Mitsios, 
et al. 2007), HIV-associated neurodegeneration, and dementia (Meyne, et al. 2009; Roberts, et al. 
2010).  All of these conditions share some aspect of dysregulated neuronal functioning in 
common with TBI, which suggests that PrPC is a potential biomarker for TBI as well.  
Additionally, recent studies have shown that patients with cerebrovascular disease or vascular 
endothelial damage had higher levels of plasma PrPC than control values (Krupinski, et al. 2008; 
Simak, et al. 2002; Starke, et al. 2002).  As the gross pathology of TBI often includes diffuse 
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microlesions throughout the cerebrovasculature as well as damage to the BBB, there may be 
additional non-neuronal derived PrPC released into the system circulation following TBI.  In 
summary, there is a wealth of evidence that suggests that CNS-localized soluble PrPC is released 
into the systemic circulation following TBI.  
 
This thesis will discuss the background information and rationale behind exploring the 
use of PrPC as a novel TBI biomarker.  The design of an animal blast exposure experiment as 
well as a human pilot study in sports concussion will be described along with the resulting data 
collected.  From these findings, this thesis will show that PrPC is a novel biomarker of TBI. 
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Section 1.  Cellular Prion Protein (PrPC) 
1.1. Background 
Stanley Prusiner first discovered the cause of a rare neurodegenerative disease affecting 
sheep and goats called scrapies, which resulted in unusual behavior often accompanied by 
scraping, hence the name, of their fleece on trees and rocks to relieve their itching sensation 
(Prusiner 1982).  Prusiner discovered that the scrapies causing agent was insensitive to nucleic 
acid modification but was partially sensitive to various protease treatments, thus determining the 
causative agent to be made of protein, despite its high resistance to digestion.  From this finding, 
Prusiner coined the new term “prion” for small proteinaceous infectious particle.  Investigators 
were able to soon after purify the infectious scrapies prion protein (PrPSc) and found that besides 
it being the cause for disease in animals, there was a strong likelihood that a similar protein 
purified from humans with neurodegenerative Creutzfeldt-Jakob disease (CJD) could also cause 
disease in humans as both share common structural features, antigenicity, and resistance to 
proteinase K hydrolysis (Bendheim, et al. 1985; Prusiner 1986).   
 
Using purified preparations of hamster brains infected with scrapies, the cDNA sequence 
of the infectious PrPSc was mapped out revealing a single copy gene (Prnp), which encodes for a 
253-residue protein, on human chromosome 20 present in both infected and non-infected brain 
extracts, as well as in murine and human brains (Oesch, et al. 1985).  Furthermore, this study 
found that specific antiserum detected prion protein in infected brain tissue, and to a lower extent 
in non-infected tissue.  After proteinase K digestion, however, prion protein in infected neural 
tissue remained while that in non-infected brains were completely degraded.  These findings 
provided evidence that prion protein was normally expressed in neural tissue, and that the 
infectious PrPSc was likely derived from this endogenously expressed protein that somehow 
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shows higher protein content, later discovered to be due to aggregated plaque formation, as well 
as becoming resistant to protease in infected tissue, likely through post-translational processing 
(Aguzzi & Calella, 2009).  Efforts to determine the chemical trigger for the synthesis of the 
infectious PrPSc from endogenous cellular prion protein (PrPC) found no likely candidates, 
suggesting pathogenesis is propagated by conformational changes in the normal protein.  
Fourier-transform infrared spectroscopy analysis determined that although PrPC and PrPSc 
possess the same amino acid sequence, their secondary structures were extremely different (Pan, 
et al. 1993).  PrPC is composed of higher α-helical content (45%) with two short stretches of β-
sheets (3%) whereas the misfolded PrPSc conversely has lower α-helices (30%) and much higher 
β-sheets (45%) (Pan, et al. 1993).  This drastic conformational change is responsible for PrPSc’s 
resistance to proteolysis as well as promoting misfolding conversion, aggregation, and formation 
of amyloid fibrils and plaques in neuronal tissue that can eventually cause apoptosis and death of 
the host (Aguzzi and Calella 2009).  Thus, prions are unique in that both the infectious agent and 
target protein are the same. 
 
Since its discovery, PrPC is often studied for its role as the causative precursor agent for 
the neurodegenerative diseases of transmissible spongiform encephalopathies (TSEs) in both 
humans (i.e. Kuru, CJD) and animals (i.e. Scrapies, Mad Cow disease), but research over the past 
decade has revealed the normal protein to be involved with many physiological processes.  The 
PrPC has been identified in many mammalian species and other vertebrates sharing similar 
sequence and structural elements with little variation across, suggesting the protein is 
evolutionarily conserved (Wopfner, et al. 1999).  The normal PrPC isoform is constitutively 
expressed throughout the CNS by neurons, between synapses, astrocytes, axons, brain 
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microvascular endothelial cells, and microglia (Bremer, et al. 2010; Brown 2001; Brown and 
Mohn 1999; Fournier, et al. 2000; Moser, et al. 1995; Viegas, et al. 2006).  Within the brain, 
PrPC is most concentrated within the hippocampal formation; septal, caudate, and thalamic 
nuclei; dorsal root ganglia cells; and large-diameter dorsal root axons (Bendheim, et al. 1992).  
PrPC is a 32 kDa glycoprotein located along the outer leaflet of the plasma membrane in dynamic 
lipid raft microdomains attached by a glycosyl-phosphatidyl-inositol (GPI) anchor (Stahl, et al. 
1992).  PrPC is constitutively recycled between the cell surface and endocytic compartment via 
clathrin-mediated internalization with the majority of protein (95%) returning to the cell surface 
intact and the remainder being proteolytically digested (Shyng, et al. 1994; Shyng, et al. 1993).  
PrPC expression in extracerebral tissues can be detected in circulating leukocytes, heart, skeletal 
muscle, lung, intestinal tract, spleen, testis, ovary, and other organs indicating extraneous non-
neuronal roles for this protein.  However, PrPC is predominantly expressed within the brain and 
is involved in important neurological functions.   
 
1.2. Structure 
The full-length 253 amino acid long prion precursor polypeptide is synthesized and then 
translocated into the endoplasmic reticulum (ER) where it undergoes post-translational 
modifications before reaching its mature form.  Within the ER lumen, PrPC is cleaved at both its 
amino (N)-terminal signal peptide and hydrophobic carboxy (C)-terminal segment leaving a 208 
amino acid long protein in the process.  PrPC undergoes N-linked glycosylation as carbohydrate 
moieties are added at residues N181 and N197 within the ER that serve the function of 
stabilizing the protein’s structure (Zuegg and Gready 2000).   Additionally, a GPI anchor moiety 
attaches at position 230 within the ER allowing PrPC to link to the cell’s plasma membrane and 
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is essential for the protein to be cycled back and forth from the endosome.  Aside from secreted 
soluble PrPC, which is predominantly extracellular, there are also two variant forms of PrPC that 
can span the plasma membrane with either the N- or C-terminus facing outwards from the cell 
(Stewart, et al. 2001).  The mechanism determining the amount of formation for these three 
variants is not yet understood. 
 
The N-terminal proximal half is largely unstructured, whereas the C-terminal region is 
distinguished by its globular domain comprised of three α-helices interspersed by two double 
stranded anti-parallel β- sheets, followed by its GPI anchor at the very end (Aguzzi and Calella 
2009).  Ion pairing between α-helices, intramolecular binding between β-sheets, as well as a 
disulfide bridge between cysteine residues 179 and 214 act to stabilize the protein’s secondary 
structure within the C-terminal.  Conversely, the N-terminal region is considered disordered and 
flexible while lacking secondary structure.  This region contains a central domain between 
residues 95 to 133, which is comprised of a charged cluster and hydrophobic core.  The central 
domain’s function is not entirely clear, but conformational study suggest it is the primary target 
of PrPSc-induced protein misfolding (Taraboulos, et al. 1990).  It is likely that conformational 
change in the central domain reveals binding sites, specifically at residues 106-126, which 
promotes cytotoxicity by activating caspase-3, thus compromising the plasma membrane leading 
to apoptosis (Vilches, et al. 2013).  Almost the entire N-terminal region sequence constitutes a 
basic motif , which is essential for transport of the protein through the secretory pathway to the 
plasma membrane as well as its internalization via association with the transmembrane low-
density lipoprotein receptor-related protein 1 (LRP1) (Nunziante, et al. 2003; Parkyn, et al. 2008; 
Sunyach, et al. 2003).  Recently it has been discovered that positively charged N-terminal 
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sequences at residues 23-31 and 95-105 can bind amyloid β (Aβ) oligomers, an association 
which has been postulated by different investigative groups to be necessary for or inhibits Aβ-
mediated cytotoxicity (Fluharty, et al. 2013; Lauren, et al. 2009).  And finally, the N-terminal 
contains five glycine-rich Octapeptide repeats (OR) from residues 51 to 90 that are involved with 
important functions to be discussed below (Hooper, et al. 2008).  See Figure 1.1 for PrPC 
primary structure illustration. 
 
Figure 1.1.  PrPC primary structure schematic.  OR: Octapeptide Repeats; CC: Charged 
Cluster; HC: Hydrophobic Core; B1/2: β-sheets 1 and 2; H1/2/3: α-Helices 1, 2, and 3. Arrow at 
residue 23 indicates cleavage site of N-terminal signal peptide.  Disulfide bond shown between 
residue 179 and 214.  Carbohydrate moiety N-glycosylation sites at N-181 and N-197 positions. 
 
 
1.3. Role 
Given that PrPC is likely expressed in all vertebrates and shares mostly conserved sequence and 
properties, it is within reason to consider that the protein plays a fundamental role.  Animal 
studies using PrPC-knockout strains of mice showed that phenotypically there was no gross 
disturbances in behavior and development (Bueler, et al. 1992; Manson, et al. 1994).  A possible 
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explanation for this lack of change is that there are compensatory mechanisms that carry out 
PrPC’s functions.  However, this suggestion is highly disputed as other studies provide evidence 
of PrPC-knockout mice displaying altered behavior due to disrupted circadian rhythm (Tobler, et 
al. 1996), changes in electrophysiological signaling (Colling, et al. 1996), abnormal long-term 
potentiation and γ-Aminobutyric acid (GABA)-inhibition (; Collinge, et al. 1994) .  Cell culture 
study shows that PrPC-deficient neuronal lines are less viable and more susceptible to oxidative 
stress (Brown, et al. 1997b) and toxicity (Kuwahara, et al. 1999) compared to wild-type cells; .  
Due to PrPC’s high expression in the brain, especially between synapses, both pre- and post-
synaptically, it is not surprising that the protein plays an important role in neural transmission 
(Collinge, et al. 1994; Haeberle, et al. 2000; Herms, et al. 1999; Prusiner 1982; Sales, et al. 
1998).  Examination of neuronal pathways within the hippocampus of PrPC-knockout mice show 
reduced excitability in hippocampal granule cell layers (Colling, et al. 1996) as well as mossy 
fiber pathway reorganization, which promotes epileptiform activity (Colling, et al. 1997).  Taken 
together, studies investigating PrPC-deficiency at whole animal, tissue, and cellular levels 
indicate that the protein is highly involved in regulating the perineuronal environment.  
Discussed below are several functions of PrPC implicated in neuronal homeostasis in addition to 
evidence that collectively suggests PrPC plays a neuroprotective role in the CNS overall.  
 
1.3.1. Metal Ion Binding 
As aforementioned, the N-terminal half of PrPC contains five OR segments consisting of 
one incomplete sequence (PQGGTWGQ) followed by four functional ones (PHGG(G/S)WGQ) 
(Sumudhu, et al. 2001).  Within each functional repeat is a histidine residue capable of binding 
one Cu2+ ion.  Binding affinity for one Cu2+ atom is low, but when binding multiple atoms the 
 
10 
 
affinity increases significantly suggesting the first binding event facilitates subsequent copper 
saturation.  Structural binding analysis of the N-terminal encompassing the OR shows additional 
histidine residues capable of binding copper at residues 96 and 111; in total PrPC can be saturated 
with 4-6 Cu2+ ions (Brown, et al. 1997a; Liu, et al. 2011).  Upon binding to copper, the OR 
undergoes conformational changes adopting a loop-like and β-sheet structure (Zahn 2003).  
Copper-bound PrPC then translocates laterally out from lipid rafts into detergent-soluble regions 
of the plasma membrane where it rapidly undergoes endocytosis via clathrin-coated pits 
(Hooper, et al. 2008).  At physiological levels copper is an important element in CNS 
development, but when in excess as implicated in various neurological disorders, there may be 
production of free radicals leading to mitochondrial, DNA, and overall cell damage (Desai and 
Kaler 2008).  Comparison of crude membranes, synaptosomes, and endosomes derived from 
PrPC-knockout mouse brain show drastically reduced (80%) intracellular copper content 
compared with wild-type (Brown, et al. 1997a).  Considering the importance of copper within 
the CNS along with evidence of impaired uptake with diminished PrPC, the protein is likely a 
major contributor towards synaptic homeostasis.  Besides copper, the metal binding regions 
within the PrPC N-terminal are also able to bind other divalent metal cations such as nickel, zinc, 
iron, and manganese with decreasing affinity (Jackson, et al. 2001; Singh, et al. 2010). 
 
In a similar manner to copper, PrPC is also able to bind and facilitate Zn2+ uptake within 
cells through its OR region with lower binding affinity than copper (Pauly and Harris 1998; 
Perera and Hooper 2001; Watt, et al. 2012).  Introduction of other metal ions such as manganese 
and iron elicited no direct PrPC-mediated binding or internalization; however, PrPC can 
alternatively affect intracellular iron content through an unidentified process (Pushie, et al. 
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2011).  Upon cellular depolarisation, vesicle packaged zinc is released from the pre-synapse into 
the synaptic cleft, which is then taken up into the cytoplasm of the post-synaptic neuron via zinc 
transporters or activated voltage-gated calcium channels α-amino-3-hydroxy-5-methyl-4-
isoxazoleproprionate (AMPA) receptors and N-methyl-D-aspartate (NMDA) receptors (Sensi, et 
al. 2009).  PrPC was found to mediate zinc uptake by interaction with GluA1- and GluA2-
containing AMPA receptors (Watt, et al. 2012).  Studies examining brains of animals with 
compromised PrPC, due to mutation or PrPSc infection, shows that zinc uptake is disrupted.  As 
zinc deficiency negatively affects neurogenesis and increases neuronal apoptosis while excess 
release damages post-synaptic neurons, PrPC is important for maintaining this narrow 
homeostatic range (Plum, et al. 2010; Szewczyk 2013).  Thus, PrPC is involved in zinc sensing 
and scavenging required to maintain homeostasis, the dysregulation of which can be associated 
with neurodegenerative diseases such as Alzheimer’s disease (AD). 
 
1.3.2. Anti-oxidative properties 
PrPC-mediated endocytosis of copper was shown to be important for cellular Cu-Zn 
superoxide dismutase (SOD) activity, which indicates the protein is involved in oxidative stress 
resistance (Brown, et al. 1997a; Brown, et al. 1999; Pauly and Harris 1998; Perera and Hooper 
2001).  Evidence for this notion is seen in a study using cerebellar slice preparations from wild-
type, PrPC-deficient, and PrPC gene-reconstituted transgenic mice (Herms, et al. 1999).  Since 
hydrogen peroxide is decomposed to form highly reactive hydroxyl radicals when combined with 
excess synaptic concentrations of metal ion Cu2+, which in turn damages and reduces synaptic 
activity, investigators determined that higher synaptic responses positively correlated with 
increasing expression of copper-sequestering presynaptic PrPC.  Additionally, PrPC-deficient 
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cells display reduced SOD activity and are more susceptible to oxidative stress and copper 
toxicity (Brown, et al. 1998a; Brown, et al. 1997b).  During oxidative stress there is a 
compensatory induction of anti-oxidative enzymes such as SOD, which apparently functions in 
concert with PrPC.  The copper binding site located on the OR region prevents the formation of 
reactive oxygen species by promoting the reduction of Cu2+ to Cu+ to prevent excessive redox 
cycling and reactive oxygen species formation (Liu, et al. 2011).  Additional evidence of PrPC’s 
anti-oxidative ability is that cells expressing PrPC are more resistant against manganese-induced 
oxidative stress and apoptosis as compared to PrPC-knockout mice (Choi, et al. 2007).  Study 
using TSE-infected brain tissue shows loss of normal function of PrPC due to misfolded plaque 
formation resulting in depleted copper-dependant anti-oxidative activity as well as manganese-
induced oxidative stress (Johnson, et al. 2013).  Thus, PrPC plays a neuroprotective role by 
promoting ion trafficking and homeostasis within the extracellular micro-environment. 
 
1.3.3. Excitotoxicity Modulation 
Of all the cell surface protein interactions with PrPC, the most intriguing and perhaps well 
studied over the past decade has been with glutamate receptors, both metabotropic and 
ionotropic.  The three classes of ionotropic receptors, AMPA, kainate, and NMDAR have been 
shown to interact with PrPC (Beraldo, et al. 2011; Carulla, et al. 2011; Kleene, et al. 2007; Mayer 
2005; Um, et al. 2013; Watt, et al. 2012). A study using PrPC-deficient mice found the animals 
displayed increased NMDAR-dependent excitability and subsequent excitotoxicity due to lost 
attenuation of PrPC on NR2D subunits (Khosravani, et al. 2008).  Most recently, interaction 
between PrPC and NR2B subunits of NMDR has been demonstrated, which may have a role in 
attenuating NR2B-dependent excitatory function of NMDARs (Pham, et al. 2014).  Furthermore, 
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in the brain of a pre-diabetic animal model this interaction is compromised due to PrPC 
suppression combined with overexpression of NR2B subunit protein compared with normal 
wild-type brains.  Excessive NMDAR activity mediates increased Ca2+ entry into neuronal cells, 
thus contributing to excitotoxic death.  Studies utilizing animal stroke models showed that there 
was a time-dependent upregulation in expression of PrPC in ischemic brain tissue as well as the 
penumbric region following focal ischemia compared to untreated brains (Mitsios, et al. 2007; 
Shyu, et al. 2005).  Moreover, the upregulated PrPC was shown to colocalize with neuron, glia, 
and vascular endothelial cells likely reflecting a broad adaptive response to ischemia and 
hypoxic conditions.  This is apparent as evidenced by transgenic animal studies showing 
overexpression of PrPC reduces volume of cerebral infarction (Shyu, et al. 2005) compared with 
PrPC-deficient mice whose neuronal cells are also susceptible to NMDA-dependent cell death 
(Spudich, et al. 2005).  This evidence supports the notion of PrPC’s adaptive response role as 
purported in an earlier animal stroke study, which showed upregulation of PrPC within the 
ischemic hemisphere (Weise, et al. 2004).  This effect was most significant in the acute period 
following insult, the duration of which depended on the extent of neuronal damage.  Clinical 
study using stroke patients provided evidence that PrPC expression is increased within the peri-
infarcted brain tissue in the neuronal soma, endothelial cells of micro-vessels, and pro-
inflammatory immune cells (Mitsios, et al. 2007).  Increased PrPC within the peri-infarcted 
region may influence hypoxia-induced cell damage, the association of which has been recently 
confirmed in animal studies showing that hypoxia-inducible factor-1 α can regulate PrPC 
expression and protects against neuronal damage (McLennan, et al. 2004).  Since NMDA 
activation can occur as a result of ischemia/hypoxia, it is likely that upregulation of PrPC is 
necessary to attenuate receptor activity to prevent excitotoxicity.  This association of PrPC and 
 
14 
 
NMDA is particularly intriguing as various neurological conditions and disorders involve 
NMDAR over-activation such as ischemic stroke, traumatic brain injury, AD, Huntington’s 
disease, and epilepsy (Parsons and Raymond 2014). 
 
 In summary, PrPC is a unique endogenous protein mainly expressed within the CNS 
that plays a role in several important physiological functions, including neuroprotection.  If 
increased PrPC levels within the brain are indicative of an adaptive response, then perhaps 
assessing its levels within biological fluids can also be telling.  
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Section 2. A biomarker within the blood: PrPC 
2.1. PrPC in Plasma 
Using flow cytometry, investigators have discovered that PrPC is differentially expressed 
on the surface of various blood formed elements.  Mononuclear leucocyte and platelet have the 
highest surface expression of PrPC, while polymorphonuclear leucocytes and red blood cells 
(RBCs) express little to no PrPC (Cashman, et al. 1990; Dodelet and Cashman 1998; Vostal, et al. 
2001).  The source of PrPC within blood cells can be traced to within the bone marrow where it is 
expressed on all long-term hematopoietic stem cells, and are required for maintaining self-
renewal (Zhang, et al. 2006).  Following hematopoiesis, platelet-derived PrPC accounts for the 
majority of cell-expressed PrPC in whole blood.  Multiple studies have shown that following 
platelet activation, there is a drastic increase in PrPC expression compared to resting cells 
(Vostal, et al. 2001).  Additionally, upon stimulation of platelet aggregation and adhesion, 
soluble PrPC is released from the plasma membrane (Perini, et al. 1996).   In contrast, RBCs 
express approximately four fold less PrPC than platelets, but due to their quantity outnumbering 
platelets by twenty fold they are a greater contributor towards blood PrPC levels.  However, there 
is no definitive consensus upon the contribution of PrPC by these fractions based on varying 
detection sensitivity across studies (Panigaj, et al. 2011; Vostal, et al. 2001).  Endothelial cells, 
another contributor towards constitutive plasma PrPC levels, have been shown to release PrPC 
expressed in microparticles, such as exosomes, during apoptosis (Simak, et al. 2002).  Thus 
endothelium-derived PrPC within the plasma is likely a result of regular cell turnover of the 
vascular lining. 
 The act of using prion protein in blood as a biomarker has only recently become 
prominent due to cases of iatrogenic transmission of variant CJD via blood transfusion arose in 
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Great Britain (Wroe, et al. 2006).  Biological fluids and tissue from TSE-infected animals, such 
as cows with BSE, carry a high potential to spread the disease to other animals including 
humans.  In animal studies, transmission was demonstrated using blood from infected sheep that 
were symptomatic of scrapies, as well as those within the asymptomatic preclinical phase 
(Houston, et al. 2000; Houston, et al. 2008).  Furthermore, transmission was demonstrated after 
transfusion of cellular blood elements, plasma as well as the cryoprecipitate fraction of plasma 
(Brown, et al. 1998b).  Knowing that blood cells express PrPC on their surface combined with the 
fact that the pathogenic misfolded PrPC isoform acts as a template for conformational conversion 
of normal protein into nascent PrPSc, clearly the infectious potential of TSEs can be carried 
within blood.  The earliest methods for detecting TSE-causing PrPSc relied on post-mortem 
testing of brain tissue, but testing for its presence in biological fluids such as blood remained 
difficult.  Validation of blood screening procedures required testing on thousands of healthy 
samples in addition to CJD-positive ones. 
 
2.2. PrPC as a Biomarker 
Early screening procedures focused on qualitative detection of only toxic prions because 
quantification for PrPC was considered to have little clinical value in detecting disease.  
However, an under-appreciated report by Völkel and coworkers had emerged years earlier in 
which they quantified plasma PrPC as a biomarker for a broad spectrum of neurologic diseases 
including AD, Parkinson’s disease (PD), and dementia, with a particular emphasis on CJD 
(Völkel, et al. 2001).  Using enzyme linked immunosorbent assay (ELISA) techniques, Völkel’s 
group found that plasma PrPC was elevated in patients with neurodegenerative diseases when 
compared with healthy control samples.  Intriguingly, elevated plasma prions from CJD patients 
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was protease K sensitive and thus the non-pathologic isoform, which is counter intuitive to past 
observations of increased proteinase-resistant PrPSc in CJD cases (Wroe, et al. 2006).  It is 
possible that PrPC expressed on the surface of components of the blood such as T and B 
lymphocytes as well as platelets are released when the cells become activated in such disease 
states (Halliday, et al. 2005; MacGregor, et al. 1999).  Another possibility is that PrPSc infection 
in the brain results in upregulation of PrPC as an adaptive response against glutaminergic 
excitotoxicity in neighboring cells, due to significant degeneration and cell damage, 
subsequently leading to increased protein shedding from the CNS (Ankarcrona, et al. 1995).  To 
show PrPC is capable of crossing the blood brain barrier (BBB) and entering the bloodstream 
from the CNS, Banks and coworkers used radiolabeled PrPC to demonstrate bi-directional 
transport from the systemic circulation to the brain tissue and from the cerebrospinal fluid (CSF) 
to peripheral tissues with varying region-specific tissue uptake (Banks, et al. 2009).  They further 
postulated that PrPC levels are maintained in a steady state equilibrium across the BBB, and that 
perhaps elevated concentration within the circulation is a response to certain pathological or 
neurodegenerative states. 
 
More recent studies have investigated using soluble PrPC as a biomarker for human 
immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) (Megra, et al. 
2013; Roberts, et al. 2010).  These studies examined HIV-1 infected individuals with HAND, 
dementia, encephalitis, or without neurological impairment, as well as a comparable animal 
model of simian immunodeficiency virus (SIV)-infected macaques with encephalitis.  In HIV-1 
infected individuals with HAND, dementia, and encephalitis, as well as SIV-1 infected animals, 
there was evidence of increased PrPC expression within astrocytes and neurons along with 
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elevated CSF concentration, which positively correlated to the degree of neurological 
impairment or encephalitis when compared against non-infected controls and those infected 
without impairment (Roberts, et al. 2010).  Plasma PrPC concentration was also evaluated which, 
as opposed to CSF levels, were decreased in all HIV-infected individuals compared to healthy 
controls.  It is noteworthy that their study provides little information describing characteristics of 
the human controls included nor did they assay a sufficient number (n=3) of normal samples to 
draw conclusions from.  Conversely, their animal experiments show that PrPC was persistently 
elevated within the plasma at multiple time points post-infection (7-56 days) compared to 
controls.  The authors do not speculate on these opposing findings, but one must consider that 
their animal experiments were well controlled for genetic and environmental influences as 
opposed to a relatively diverse pool of humans.  Moreover, animal blood samples were taken 
relatively early compared to human participants who may have had HIV for years prior to the 
study.  Taken together, their evidence suggests that PrPC is a biomarker of neurodegeneration, 
which becomes upregulated in the brain and subsequently secreted or shed into biological fluids..  
However, this assumption may also work in the opposite manner as another study showed, using 
a larger sample set, that CSF PrPC levels are decreased in various neurodegenerative conditions 
or diseases compared to control (Meyne, et al. 2009).  Similarly, PrPC within human CSF was 
found to decrease to near undetectable levels, without apparent PrPC breakdown products, one 
week after individuals suffered spinal cord injury suggesting CNS-specific uptake of the protein, 
perhaps for neuroprotection (Carnini, et al. 2010). 
 
Another potential means of increased plasma PrPC from the CNS was discovered when 
investigating calpains, which are a class of ubiquitously expressed cytosolic non-lysosomal 
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cysteine proteases that require calcium to function.  When there is excessive glutamate-mediated 
influx of calcium into the neuron, such as following a cerebrovascular insult or even traumatic 
brain injury (TBI), hyperactivation of available calpains occurs allowing for unregulated 
proteolysis of both specific and non-specific proteins leading to tissue damage (Liu, et al. 2008).  
The resulting proteolytic cleavage products from increased calpain activity can be used as 
biomarkers for the presence of neurological degeneration or injury.  However, when calpains are 
introduced to brain lysates from PrPC-expressing mice there is surprisingly no appearance of 
PrPC breakdown products, despite the protein’s well known susceptibility to proteases (Wang, et 
al. 2012).  This same study also showed that after neurotoxic treatment with subacute doses of 
maitotoxin and NMDA resulting in calcium influx, breakdown products are still not detected.  
But instead of smaller fragmented protein products, they found that full-length intact PrPC 
molecules were actually released into the culture media, in a toxicity dependent manner, via a 
process completely independent of calpain and other cytosolic proteases.  This indicates that, by 
some yet unidentified cleavage event, full-length PrPC is released as a result of cell stress. 
  
Another source for plasma PrPC can be found in microvesicular exosomes isolated from 
plasma, which express PrPC (Ritchie, et al. 2013).  Moreover, cultured neurons have been shown 
to release PrPC-carrying exosomes into the surrounding media, which is likely a means of 
maintaining homeostasis in vivo as mentioned above (Fevrier, et al. 2004).  Exosomes are 
extremely small cell-derived microvesicles (30-100 nm) that are formed when internal 
multivesicular bodies fuse with the plasma membrane and then secreted into the extracellular 
environment (Keller, et al. 2006).  Exosomes can be derived from many different cell types 
including immune cells, platelets, and neurons and are detectable within biological fluids such as 
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blood plasma (Caby, et al. 2005).  Exosomes can transfer molecules, proteins, metabolites, and 
genetic material from one cell to another via membrane vesicle trafficking without requiring 
direct cell contact or axonal transport.  In this way, exosomes have been reported to be involved 
in cellular functions including protein secretion, RNA and protein transfer, cell-to-cell signaling, 
and even in neuroinflammatory responses, such as following TBI (Gupta and Pulliam 2014; 
Sharma, et al. 2013).  Exosomes thus have the potential to affect cells up to long distances from 
their origin as they are transferred in biological fluids like plasma, and may be used as miniature 
surrogates of their origin cell’s status upon secretion.  For example, cultured neurons following 
PrPSc infection secrete exosomes carrying both PrPC and PrPSc into the surrounding media 
(Fevrier, et al. 2004).  Another scenario for exosome shuttling and release of PrPC within plasma 
may be a result of a disintegrin and metalloprotease (ADAM)10.  ADAM10 can act at the cell 
surface to cleave other surface proteins including PrPC (Altmeppen, et al. 2011).  Upon calcium 
influx, such as from stroke or TBI, there is augmented release of functional ADAM10-containing 
exosomes that is believed to be the primary contributor towards ectodomain shedding of soluble 
molecules, perhaps even PrPC (Stoeck, et al. 2006). 
 
 There is a great deal of evidence describing the possible sources of soluble PrPC 
within blood plasma.  There seems to be a constitutive release and even uptake of soluble 
PrPC within the CNS that is normally a part of its homeostatic regulation.  However, in 
neurodegenerative states there is likely increased PrPC release from the CNS into the 
periphery.  Such conditions have garnered much attention in particular as it pertains to 
TBI survivors that may develop long-term neurological deficits. 
  
 
21 
 
Section 3. Traumatic Brain Injury (TBI) 
Traumatic brain injury (TBI) is the result of external mechanical forces exerted on the 
brain as a result of direct or indirect physical impact to the body.  Direct physical TBI can occur 
as a result of falls, vehicle accidents, assaults, and sports, which will be of particular focus from 
here on, may be a result of impact to the head, face, neck, or other parts of the body by a solid 
surface or object, or even another person.  This form of TBI involves sudden linear or angular 
acceleration/deceleration forces that are known to cause discrete, focal lesions at points of 
impact, shearing stress on the brain, and BBB disruption (Marchi, et al. 2013; Patel and Reddy 
2010).  Conversely, indirect TBI can occur as a result of transferred kinetic energy such as from 
exposure to explosive blast waves commonly experienced by military service members.  Unlike 
conventional head injuries such as in sports, blast-induced TBI (bTBI) produces no linear or 
angular forces as the necessary whiplash or jolting motion of the head are absent without 
involvement of the cervical spine.  Instead the mechanism of injury for bTBI involves various 
components of the blast contributing towards a heterogeneous pathology complex.  Although 
both forms of TBI may seem grossly different from one another, in actuality they may be very 
similar as most head injuries are mild in severity with most of the brain damage occurring as a 
result of secondary injury mechanisms being active for an extended period of time after the 
initial insult.  Athletes and military service members who have suffered multiple mild-TBI 
display altered mental status; impaired cognitive, motor, and social function; increased risk for 
AD, amyotrophic lateral sclerosis (ALS), PD, and chronic traumatic encephalopathy (CTE)-like 
symptoms (Goldstein, et al. 2012; McKee, et al. 2009; McKee and Robinson 2014; Omalu, et al. 
2005).  TBI is a growing epidemic because victims of sports- or blast exposure-TBI may not be 
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accurately identified as injured by clinicians perhaps due to insufficient diagnostic test results or 
even under-reporting of symptoms by those injured. 
 
3.1. Sports Concussions 
Concussion is a complex pathophysiological process and is considered as a subset of mild 
TBI (mTBI), which results in transient disturbances of brain function as a result of head injury.  
Concussions are the consequence of a direct or indirect blow that results in a sudden angular 
acceleration or deceleration of the brain tissue within the calvarium.  In the US alone, 3.8 million 
cases of sport-related concussions occur annually, and high-contact sports such as American 
football, hockey, rugby, soccer, and basketball have the highest incidence of concussion 
(Daneshvar, et al. 2011; Harmon, et al. 2013; Langlois, et al. 2006; Meehan and Micheli 2011).  
Considering unreported cases by victims, it is estimated that the incidence of sport-related 
concussions is even higher (Meehan, et al. 2013). Clinical manifestations of sport-related 
concussions may include a variety of symptoms such as loss of consciousness, headache, 
dizziness, amnesia, nausea, confusion, fatigue, sleep disturbances, balance and memory 
impairment, slurred speech, and light sensitivity.  At the molecular pathophysiological levels, 
most of these symptoms are a result of significant alterations in ionic balance, neurotransmitter 
activation, axonal integrity, and energy metabolism in the CNS (Barkhoudarian, et al. 2011; 
McKee, et al. 2014).  Most sport-related concussions are benign and athletes typically recover 
within 7-10 days or even longer if given adequate rest and appropriate therapy.  During this 
sensitive period of recovery, individuals are extremely at risk should they suffer a subsequent 
head injury.  Multiple concussions within a short period of time may lead to devastating long-
term sequelae and prolonged functional impairment, including post-concussive syndrome, 
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neurodegenerative diseases, CTE, as well as rare catastrophic consequences called second impact 
syndrome (Boden, et al. 2007; Gavett, et al. 2011; Halstead and Walter 2010; Omalu, et al. 
2005).   
 
In high-contact sports it is not uncommon for athletes to suffer multiple head injuries 
resulting in concussion, but they may also suffer many more sub-concussive impacts that can 
potentially compile over time with worsening neurological degeneration.  An animal model of 
repetitive mTBI showed persistent mild deficit in balance and coordination, increased expression 
of axonal injury marker glial fibrillary acidic protein (GFAP), as well as hyperphosphorylation of 
tau, a cellular microtubule-associated protein (Kane, et al. 2012).  In humans and animal models 
of TBI, there is evidence of microvasculature and BBB damage, cerebral hemorrhaging, 
neuroinflammation, edema, oxidative stress, ischemia, cell death, and diffuse axonal injury (Foda 
and Marmarou 1994; Fritz, et al. 2005; Homsi, et al. 2009; Marmarou, et al. 1994).  There is 
even evidence of acute elevation in AD-associated Aβ40 and 42 peptides as well as increased 
levels of β-site APP cleaving enzyme 1 (BACE1) and γ-secretase component presenilin-1 
(PSEN1) (Loane, et al. 2009).  This shift in normal APP processing towards deleterious peptide 
formation combined with widespread tau phosphorylation shows there is an associative risk 
between brain injury and AD as shown by amyloid β deposition within axons as early as a few 
days following a TBI event (Johnson, et al. 2012; Smith, et al. 2003).  When combined, evidence 
from TBI animal models and gross pathology of post-mortem brains from athletes who have 
suffered repetitive TBI suggests that there are a myriad of secondary injury mechanisms 
occurring over time that contribute towards progressive neurodegeneration like CTE, and 
increased risk for diseases, such as AD, PD, and ALS (Omalu, et al. 2005).  Since secondary 
 
24 
 
injury mechanisms are likely occurring at the cellular level, it is not surprising that most mTBI 
cases show no abnormalities on computed tomography (CT) and conventional magnetic 
resonance imaging (MRI).  Identifying those athletes affected by concussion remains a 
challenging issue for health care clinicians using current standards of care (Belanger, et al. 
2007).  Thus, it is absolutely essential to identify whether concussion occurred so as to manage it 
properly and avoid repetitive injuries.  
 
3.2. Blast-induced TBI 
Blast-induced TBI (bTBI) is the result of explosive shock waves impacting the body.  
This is different from conventional impact-related TBI as blast waves directly transfer kinetic 
energy throughout the body while the former requires an acceleratory force component. 
Although bTBI primarily affects military personnel (to be discussed further in published work 
below in Section 5), it is also of concern for civilians exposed to blasts, such as in industrial 
accidents or urban terrorism.  Upon detonation of an explosive weapon or material, a large shock 
wave (primary blast wave) is released due to instantaneous conversion of stable material into gas 
that expands outwards from the blast epicenter.  As the primary blast wave traverses in air, there 
is increased atmospheric pressure, termed the blast overpressure (BOP) wave, as a result of air 
displacement in front of the wave.  Conversely, this overpressure wave is shortly followed by a 
pressure front below normal atmospheric level, termed the underpressure wave, which then 
equilibrates back to normal as displaced air is replaced.  Molecular and cellular mechanisms of 
brain injury following BOP are not well understood and difficult to study due to the 
heterogeneity of contributing blast by-products including the overpressure wave, heat, and 
chemicals.  This thesis will only discuss injury mechanisms related to BOP.   
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When the BOP wave makes contact with the body, not necessarily just the head, there is a 
transient surge in atmospheric pressure within hollow organs and the cardiovascular system 
(Chen, et al. 2013). This increase in overall pressure then rapidly causes an adaptive 
physiological increase in blood pressure to displace blood and return to normal pressure levels.  
The sudden surge of displaced blood is likely directed towards the cranial cavity as a result of it 
being lower in pressure as the skull is able to resist atmospheric compression from the BOP wave 
unlike the rest of the body.  Blood surging through the brain results in large-scale 
microvasculature and BBB damage, subsequently leading to activation of secondary injury 
mechanisms (Chen, et al. 2013).  Additionally, gas filled spaces such as the lung, ear, and 
gastrointestinal tract are commonly injured following blast exposure due to sudden atmospheric 
constriction and subsequent implosion of compressed gases (Mayorga 1997).  Violent 
displacement of fluids and gases within the body following blast-exposure can result in shearing 
or tearing forces due to the blast wave-induced acceleration of tissue at varying rates depending 
on their density (Nakagawa, et al. 2011).   
 
Animal study has shown that similar to mTBI, blast exposure produces very similar 
pathology as conventional TBI experiments.  Rats exposed to BOP revealed significant increase 
in reactive oxygen species, altered anti-oxidative enzyme activity, as well as expression of pro-
inflammatory mediators (Cernak, et al. 2001; Cho, et al. 2013).  This environment of oxidative 
stress and neuroinflammation resulted in neuronal cell death as well as significantly impaired 
short-term memory and learning.  BOP studies using animals and organotypic brain slice culture 
have shown that even mild intensity shock waves can cause hippocampal cell death, neuronal, 
glial, and vascular damage, astrogliosis, axonal deposition of Aβ, as well as altered cell 
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attachment and signalling (de Lanerolle, et al. 2011; Effgen, et al. 2014; Kamnaksh, et al. 2012).  
However, in contrast to non-blast TBI, blast exposure actually results in decreased brain levels of 
Aβ 40 and 42 with no change in APP processing secretases (De Gasperi, et al. 2012).  Although 
there is evidence of the development of CTE-like pathology after a single blast event in an 
animal BOP model as well as in war veterans exposed to multiple blasts, there has been no 
definitive link to developing AD besides the risk from shared pathology of neurofibrillary tau 
tangles (Goldstein, et al. 2012).   
 
Overlapping symptoms with conventional TBI as well as psychological conditions such 
as post-traumatic stress disorder (PTSD), including sleep disturbances, headaches, nausea, and 
memory loss, can produce confounding effects on diagnosis (Weinberger 2011).  In the military, 
misdiagnosis of blast exposure is very possible considering the constant duress combined with 
physical and psychological strain and trauma soldiers may face in duty that these symptoms can 
arise from.  Furthermore, under-reporting of symptoms such as headaches, dizziness, or memory 
loss by soldiers is common in part because of traditional militaristic zeal to endure one’s pain 
and hopefully “shrug it off”.  As a result, military service members are especially at risk for 
repeated blast exposure during missions as many are not given medical exemption for duty in 
comparison to those that received penetrating wounds for example. 
  
3.3. Protein Biomarkers of TBI 
 Diagnosis of TBI is especially difficult because of the heterogeneous manifestation of 
signs and symptoms with low reproducibility across different cases.  Current standards of 
diagnosis for TBI are not definitive, but are usually inferred by clinicians based on cognitive 
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impairment tests such as the Glasgow Coma Scale (GCS), which requires clinicians to score 
individuals based on ocular, verbal, and motor responses.  As a result, researchers have focused 
on screening for objective surrogate protein biomarkers specific to TBI.  Protein biomarkers are 
readily accessible in biological fluids such as plasma and serum, which may serve as valuable 
tools in identifying those who have suffered TBI.  Several potential protein biomarkers have 
been identified for TBI, of which a few have been tested in sport related concussion (reviewed in 
(Jeter, et al. 2013; Strathmann, et al. 2014; Yokobori, et al. 2013). Among these potential protein 
biomarkers, S100 calcium binding protein B (S100B), cleaved and total tau, GFAP, myelin-basic 
protein (MBP), neuron-specific enolase (NSE), ubiquitin C-terminal hydrolase-L1(UCH-L1), 
αII-spectrin breakdown products (SBDPs), 14-3-3 (Siman, et al. 2009), apolipoprotein E (apoE) 
(Kumar, et al. 2006), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF- α) have been 
widely studied for their ability to detect TBI in both sports-related and blast exposure injuries.  
However, there is no one ideal biomarker to determine TBI as many studies provide conflicting 
evidence promoting or refuting the use of certain proteins.  One of the most widely investigated 
proteins S100B, an astroglial injury marker, is increased in the blood following head trauma, but 
it can also be increased as a result of extra-cranial injuries and bone fractures (Anderson, et al. 
2001; Vos, et al. 2010).  In contrast, another clinical study found that plasma S100B levels did 
not correlate with TBI in head-injury patients upon hospital admission (Metting, et al. 2012).  
However, the same study showed that plasma GFAP was highly specific for TBI, but showed 
poor sensitivity as it was indiscernible in more than half the cases.  A multicenter cohort study 
following professional hockey players showed that plasma levels of total tau and S100B were 
significantly elevated in players one hour following concussion compared to their pre-season 
values, while NSE showed no change (Shahim, et al. 2014).  Repeated blood sampling at set 
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intervals from 1-144 hours after injury showed that protein levels for T-tau and S100B were 
elevated one hour following concussion and diminished greatly within 12 hours, with S100B 
becoming indistinguishable to preseason levels.  However, the authors also note that following a 
friendly game without contact or concussion there was a significant rise in these proteins 
compared to levels taken before the game suggesting T-tau and S100B are non-specific to TBI.  
In contrast to this cohort of hockey players, an animal BOP study examining plasma biomarkers 
two hours following blast exposure showed that plasma protein levels of NSE were significantly 
elevated in rats receiving multiple shocks compared to sham controls, but GFAP was not 
(Kamnaksh, et al. 2012).  The lack of objective protein markers for TBI should be expected to 
some extent considering the diverse nature of TBI manifestation, and remains a challenge that 
delays acute diagnosis and timely decision making regarding course of care for the injured. 
 
3.4. TBI implications towards PrPC 
Due to PrPC’s extracellular orientation, it is possible that during a concussive event, 
linear and/or rotational forces transmitted through the brain may cause damage resulting in the 
tenuously bound PrPC to become dislodged and collect within the systemic circulation in the 
acute period following injury.  Another factor that could potentially increase the amount of free 
PrPC to collect within the bloodstream is that TBI can cause BBB damage allowing for increased 
permeability.  An animal model of TBI found that PrPC-deficient mice manifested larger lesion 
volume as well as more extensive BBB damage compared to wild-type controls  (Hoshino, et al. 
2003).  As PrPC is expressed within endothelial cell junctional domains of the BBB, it likely 
serves a protective function, as suggested by the previously mentioned animal study, and may be 
upregulated in response to TBI-induced damage (Viegas, et al. 2006).    Following this acute 
 
29 
 
period of potential shedding, it is likely that PrPC is upregulated within and surrounding damaged 
areas of the brain in which secondary injury mechanisms are active such as oxidative stress and 
inflammation.  An animal BOP model showed that 24 hours following blast exposure Prnp is 
one of many upregulated genes within the brain (Kochanek, et al. 2013). Unfortunately due to 
the investigators’ study design, both Prnp mRNA and its protein product did not meet the 
upregulation criteria for robustness as some other classical injury markers did, and was not 
further explored.  Additionally, since neuronal excitotoxicity plays a major role in the 
pathogenesis of TBI, it is possible that PrPC becomes upregulated, especially within synapses 
where it can modulate overactive NMDAR following injury (Algattas and Huang 2014; Parsons 
and Raymond 2014).  As discussed in Section 1, an animal stroke model using transgenic mice 
for different levels of PrPC expression showed that PrPC serves a neuroprotective role in limiting 
brain infarction size following ischemia (Spudich, et al. 2005).  Spudich and coworker’s 
examination of affected cell signaling pathways revealed that PrPC modulates activity of integral 
extracellular signal-regulated kinase (ERK)1/2, signal transducers and activators of transcription 
(STAT)1, and the pro-apoptotic enzyme caspase-3.  Intracellular ERK1/2 signaling is highly 
active following TBI as shown by increased phosphorylation in mossy fibers of the 
hippocampus, and is thought to be involved with mossy fiber reorganization, which may pose a 
risk of seizure for those injured (Hu, et al. 2004).  Since PrPC-knockout mice also show mossy 
fiber network changes, the protein is likely involved in regulating ERK1/2 signaling as a 
neuroprotective measure against epileptiform activity (Colling, et al. 1997).  STAT1 is another 
protein that shows increased activity, via phosphorylation and nuclear translocation, following 
neuronal injury such as from ischemia (Takagi, et al. 2002) or TBI (Zhao, et al. 2011).  As 
STAT1 overactivation may contribute to neuronal injury through regulating phosphorylation and 
 
30 
 
transcription of proteins related to apoptosis, it would seem that PrPC-mediated modulation of 
STAT1 is neuroprotective.  Finally, caspase-3 is a pro-apoptotic enzyme normally activated 
during programmed cell death signaling and is increased following TBI, thus contributing 
towards brain tissue loss and potentiates signal cascades towards cell death (Clark, et al. 2000).  
Although previous report suggests PrPC can down regulate capsase-3 activity (Spudich, et al. 
2005), there is conflicting evidence showing overexpression of PrPC triggers increased capsase-3 
action (Paitel, et al. 2002).  Paitel and coworkers demonstrated that proteasome inhibition, 
thereby increasing cell surface PrPC localization, potentiates PrPC-mediated caspase-3 activation 
while antibody sequestering of PrPC at the surface prevented it.  A possible consideration is that 
normal PrPC expression basally inhibits or is insufficient to activate caspase-3.  However, upon 
upregulation of PrPC, as seen in various models of neuronal injury, an alternate signaling 
pathway may become active or PrPC-signaling itself is now sufficient to activate caspase-3.  
Further speculation may point towards a compensatory cellular mechanism that triggers for 
shedding upregulated PrPC from the cell surface to prevent excess caspase-3 activation.  
Together, the evidence of PrPC’s neuroprotective role in TBI and other neuronal injury models 
suggest a concomitant damage-dependent upregulation of PrPC as an adaptive neuroprotective 
response. 
 
Other secondary injury mechanisms may likewise influence PrPC upregulation such as 
inflammation.  Neuroinflammatory mediator chemokine CC ligand (CCL)2, expressed in various 
cell types including neurons, astrocytes, and microglia, is elevated in the CNS following TBI and 
is implicated in progressive secondary brain injury (Semple, et al. 2010).  Introduction of 
recombinant CCL2 to cultured neurons has been shown to increase PrPC release within 
 
31 
 
surrounding culture media (Roberts, et al. 2010).  When this soluble PrPC-rich media is 
introduced to astrocyte culture, there is increased production of inflammatory mediators CCL2 
and interleukin-6 suggesting that PrPC can potentiate the neuroinflammatory state following 
injury.  However, others have reported that PrPC acts to attenuate T-cell dependent 
neuroinflammation (Tsutsui, et al. 2008).  Thus, more investigation is required to determine 
PrPC’s specific role regarding inflammation.  As mentioned in section 2, PrPC levels between the 
brain and extracellular environment are homeostatically maintained.  Synaptic membrane bound 
α-secretase member ADAM10 has been reported as the primary sheddase of PrPC in vivo 
(Altmeppen, et al. 2011).  Shortly following TBI, ADAM10 is active during synaptic 
reorganization (Warren, et al. 2012), which may allow increased cleavage of upregulated PrPC at 
its shared lipid raft domains.  Another possible route for increased PrPC within the circulation 
may be in exosomes as discussed in section 2 above (Fevrier, et al. 2004; Ritchie, et al. 2013).  
An interesting property of exosomes is their ability to horizontally delivery proteins, metabolites, 
as well as mRNA and miRNA to respectively allow de novo protein synthesis or modulation in 
the recipient cell (Valadi, et al. 2007).  The transfer of genetic material through exosomes has 
been shown to influence survival of nearby cells through initiation of adaptive responses to 
changes in their surrounding environment such as from TBI (Redell, et al. 2010).  Thus, 
upregulation of PrPC in and surrounding damaged areas of the brain, combined with increased 
Ca2+ trafficking as mentioned in section 2, may prompt increased exosomal packaging of cell 
surface proteins such as PrPC and its sheddase ADAM10 (Stoeck, et al. 2006).  It is unclear 
whether this cascade of events influences nearby cells in a neuroprotective manner and shall be a 
point of future study, but it does provide another possibility for PrPC release into the periphery 
from the CNS following TBI. See below figure 3.1 for schematic diagram of possible PrPC 
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cleavage products and figure 3.2 for scenario diagram of possible TBI-mediated release 
mechanisms for PrPC. 
 
 All evidence considered regarding PrPC’s structure, role, and cleavage mechanisms, 
we postulate that TBI, either from conventional impact and acceleratory forces or 
oscillating blast waves, may cause shedding of PrPC from the CNS into the extracellular 
space and pooling within the systemic circulation.  Furthermore, the cascade of secondary 
injury mechanisms initiated after injury may further promote PrPC shedding.  By utilizing 
sensitive quantification technique, we can determine the presence of injury by assessing 
plasma PrPC as a biomarker. 
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Figure 3.1. Possible breakdown products of PrPC following TBI.  β-site cleavage between 
residue 90/91 due to reactive oxygen species (ROS) produces the N2 terminal fragment.  α 
cleavage between 109/110 due to ADAM10 produces the N1 fragment.  β cleavage and α 
cleavage at site 228/229 or breakage of the GPI anchor produces the C2 fragment.  α cleavage at 
site 109/110 and cleavage at 228/229 or GPI breakage produces the C1 fragment.  α cleavage at 
site 228/229 or GPI breakage procures full-length fragment. 
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Figure 3.2. Possible release mechanisms for PrPC following TBI. (A) Normal state with PrPC 
attachment along extracellular surface of cholesterol-rich lipid rafts within the plasma 
membrane; (B) Shear stress force from TBI or oscillating waves from bTBI may cause breakage 
of the GPI anchor leading to free PrPC within the extracellular space; (C) 1) Active ADAM10, 
elevated reactive oxygen species (ROS) and CCL2 can all contribute towards 2) PrPC cleavage of 
various sized fragments; (D) 1) Elevated Ca2+ influx through overactive NMDAR contributes 
towards neurotoxicity.  Increased expression of PrPC at the cell surface acts to attenuate 
NMDAR activity resulting in 2) concomitant secretion; (E) 1) Elevated Ca2+ influx causes 
exosomal packaging of plasma membrane segments including functional ADAM10 and PrPC.  2) 
Extravesicular shedding of PrPC by ADAM10 may occur within the extracellular space leading 
to 3) its secretion (dotted).  Note: only the outermost layer of the plasma membrane (pink) is 
depicted.  Lipid raft regions are indicated by cholesterol (yellow) rich areas within the plasma 
membrane. 
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Figure 3.2. continued 
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Section 4. Materials & Methods 
4.1. Advanced Blast Simulation and Plasma Collection 
 Blast exposure procedure will be discussed in published work in section 5 below.  
Briefly, anesthetized adult, male Sprague-Dawley (S-D) rats are anesthetized with 3% isoflurane 
in 100% oxygen before being securely placed within an animal holding tube.  The S-D rats are 
positioned within the tube in such a way to allow head-only lateral exposure to the blast along 
the length of the blast tube.  The head of the animal is securely restrained atop a small platform 
by mesh netting (restraint), or not restrained (whiplash), or is covered by a protective netting 
material (net).  Helium gas pressure is built up within the pressure driver section and, depending 
on the thickness of the plastic acetate sheets barrier, will produce a single primary blast 
overpressure wave of 15-30 pounds per square inch (PSI) (103.4-206.8 kilopascals (kPa)) that 
bursts through the divider and travels along the blast tube to impact the anesthetized animal 
along the side of the head.  Reflective blast waves are prevented by the end wave eliminator 
device at the distal end of the blast tube to ensure single blast pulse exposure only.  Anesthetized 
sham blast exposure trials are also performed.  Following blast, still unconscious animals are 
removed from their holding tube and allowed to recover consciousness before being returned to 
the animal holding facility.  Following 24 hours after blast or sham experiments, animals are 
decapitated and exsanguinated.  Small blood samples are collected via potassium ethylene 
diamine tetra-acetic acid coated tubes (BD Vacutainer K2EDTA #367841) and then centrifuged 
for 10 minutes at 2000 g.  Plasma separated fraction is aliquoted within 1.5 mL Eppendorf tubes 
to be stored at -80˚C until use.  Blast exposure experiments and blood sample collection was 
performed under Dr. Thomas Sawyer and coworkers at the Defence Research and Development 
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Canada (DRDC) location in Suffield, AB, Canada.  See figure 4.1 for schematic overview of 
blast exposure procedure. 
 
Figure 4.1. Advanced Blast Simulation device.  (A) 1) Built up helium gas pressure within the 
driver section 2) ruptures the cellulose acetate diaphragm to produce a single overpressure wave 
that travels down the length of the blast tube to 3) impact the anesthetized S-D rat along the side 
of the head only. (B) Actual photograph of blast tube at DRDC Suffield (reprinted with 
permission). 
 
 
A 
B 
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4.2. Immunohistochemistry 
 At one day after blast exposure, animals were euthanized via decapitation and 
immediately perfused transcardially with ice-cold phosphate-buffer saline (PBS; 0.1 M, pH 7.4) 
followed by 4% formaldehyde (BDH #0500-4LP) in PBS fixative solution.  The brains were then 
removed from the calvarium and post-fixed with 4% formaldehyde in PBS at 4˚C overnight 
(O/N) before histological preparations.  To prevent ice crystal formation in fixed tissue sections, 
brains were dehydrated in 30% sucrose in PBS cryoprotectant solution at 4˚C until brains sank to 
the bottom of their tubes.  Brains were then immersed and bathed in Tissue-tek optimal cutting 
temperature (Tissue-Tek OCT) solution and placed within a tissue mold (Tissue-tek Cryomold).  
The mold is filled with OCT solution and then flash frozen with liquid nitrogen before storing at 
-80˚C until use. 
Coronal sections (30 µM thickness) of rat brain containing the hippocampus ipsilateral to 
blast exposure were prepared within a cryostat (Shandon Cryotome) and post-fixed as free 
floating sections.  Tissue sections are rehydrated in PBS at room temperature (RT) for 10 
minutes before permeabilization in 0.1% Triton X100 in PBS for another 10 minutes at RT.  
Sections were blocked in 2% bovine serum albumin (BSA) in PBS for 45 minutes at RT.  
Sections were gently washed in 0.5% BSA in PBS (PBB).   Sections were sequentially 
immunostained with primary antibodies and fluorescence tagged secondary antibodies against 
either phosphorylated NFH (pNFH, Covance SMI 31, 1:500, Cedarlane, Burlington, ON, 
Canada) or non-phosphorylated NFH (NFH, Convance SMI 32, 1:500, Cedarlane) and GFAP 
(Invitrogen 18-0063, 1:1000, Burlington, ON, Canada).  Primary antibody are diluted in PBB 
and added to tissue sections for incubation for 60 minutes at RT or O/N at 4˚C.  Free floating 
sections are rinsed five times in PBB.  Green fluorescent-dye tagged secondary antibody for 
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pNFH or NFH (Alexa Fluor 488 Z25002, Invitrogen, 1:1000) and red dye tagged antibody for 
GFAP (Alexa Fluor 594 Z25307, Invitrogen, 1:1000) is added to the sections for 60 minutes at 
RT.  Sections are then rinsed five times in PBB and an additional five times in PBS.  Sections are 
then counterstained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; 300nM, 
Invitrogen D1306) in PBS  for five minutes to view nuclei (blue).  Sections are washed three 
times in PBS before sections are mounted onto microscope slides with a coverslip mounted on 
topusing gelvatol in tris-[hydroxymethyl] aminomethane (Tris)-Cl solution (0.2 M, pH 8.5).   
 
Stained brain slices were viewed with a Quorum WaveFX laser scanning confocal 
microscope and images were captured with a Hamamatsu EM-CCD camera (Quorum 
Technologies WaveFX-X1, Guelph, Ontario).  Finally, captured images were stitched together 
using the software package MetaMorph (Molecular Devices) to show structures of different brain 
regions.  Areas of interest were then cropped to include approximately 500 µm sections for 
presentation.   
  
4.3. Sports Concussion Pilot Project 
4.3.1. Athletes and non-athletes recruitment 
The study was approved by the Biomedical Research Ethics Committee of the University 
of Saskatchewan, Canada (Bio # 13-195).  Members of University of Saskatchewan Huskies 
Athletic teams including Canadian football, ice hockey, basketball, and soccer teams as well as 
healthy non-athlete male and female university students were asked to participate in the 
investigation.  Individuals were asked in a questionnaire whether they were in good standing 
health without any existing illnesses or condition and whether they had recently (<6 months) 
suffered a head injury.  Those who had a pre-existing condition or had suffered a recent injury 
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were excluded from the study to prevent potential confounds.  Altogether, participants of high-
contact sports were recruited as follows: ice hockey (n=17), football (n=20), soccer (n=4), 
basketball (n=18), and wrestling (n=6).  Samples were also collected from athletes in typically 
low contact sports such as volleyball and cross country (n=11).  For normal values, 27 additional 
samples were collected from the non-athlete university student population.  In total, 103 
participants submitted a blood sample.  For summary of participant characteristics see table 6.1 
in section 6.  Initial samples submitted by athletes before pre-season training are treated as 
baselines, and should they suffer a significant head injury throughout the season a subsequent 
post-TBI sample is collected.  In total six concussed athletes were identified during the season 
using the sports concussion assessment tool (SCAT)3 concussion assessment criteria 
(Guskiewicz, et al. 2013) and their post-concussion blood samples collected 1-7 day post-
incidence depending on subjects availability.   
 
4.3.2. Plasma Separation & Storage 
All sample collection was performed following signed and informed consent prior to 
invasive procedure and sample testing as outlined by the Tri-Council Policy Statement (TCPS)2.  
Samples were alphanumerically coded for subsequent single-blinded testing.  A small sample of 
venous blood (2 mL) is collected from individuals into lithium heparin coated vacutainer tubes 
(BD vacutainer PST #367962).   Samples were immediately placed on ice to allow stable 
transport to laboratory setting.  Samples were then centrifuged at 10,000RPM for 10 minutes for 
plasma isolation.  Plasma fraction was aliquoted in 1.5 mL Eppendorf tubes and immediately 
stored at -80°C for future analysis.  
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4.4. Plasma PrPC ELISA 
 For sensitive quantification of full-length soluble PrPC, we employed an ELISA 
technique using a commercially available qualitative assay kit (Spi Bio A05201, Paris, FR) and 
modified the manufacturer’s protocol to allow sensitive and accurate quantification.  Pure full-
length recombinant PrPC (Prionatis, α-Rec Mouse PrP-RPA0101S, Zurich, CH) was used for 
producing serial dilutions (0.625—20 ng/mL) in order to establish the calibration curve for 
quantifying samples (see figure 4.2).  All samples and PrPC protein standards were diluted in the 
manufacturer’s provided dilution buffer solution (1 M phosphate, 1% BSA, 4 M NaCl, 10mM 
EDTA, and 0.1% sodium azide).  Remaining solutions and lyophilized reagents provided by the 
manufacturer were reconstituted and prepared according to the suggested protocol.  Briefly, 
overall protein concentration of individual samples was first determined in triplicate using the 
Bio-Rad DC protein assay (Bio-Rad #500-0113/0114).  Samples and standards were loaded in 
equal volume in triplicate in pre-coated 96-well microplate strips.  Diluted samples were loaded 
as such that each well contained approximately overall protein amounts of 75-100 µg.  The plate 
was then incubated O/N at 4°C with shaking to allow adequate antigen binding to well-
embedded monoclonal antibodies, specific to the 144-153 amino acid residues within the C-
terminus.  After rigorous washing (4M phosphate, pH 7.4) to remove unbound particles, the 
wells are incubated with an acetylcholinesterase- (AChE) Fab’ conjugated antibody solution 
targeting the N-terminal OR between residues 51-90 for two hours at RT with shaking to form a 
“sandwich complex” of solid phase antibody—PrPC—enzyme-conjugated antibody.  Unbound 
antibody is washed away after another cycle of washing before adding modified Ellman’s 
reagent with substrate (5,5’-dithio-bis(2-nitrobenzoic acid) or DTNB; 0.1 M phosphate buffer, 
0.5 mM DTNB, 1 mM acetylthiocholine iodide, pH 7.4).  The assay uses thiol ester 
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acetylthiocholine iodide, which undergoes hydrolysis via AChE to produce thiocholine and 
acetate.  This thiol group then reduces DTNB ion resulting in cleavage of the disulfide bond to 
produce 5-thio-2-nitrobenzoate (TNB-), which ionizes at neutral and alkaline pH to form TNB2-.  
TNB2- is responsible for producing the yellow color in solution proportional to the amount of 
captured protein (see Figure 4.3 for reaction diagram).  This colorimetric reaction and can be 
quantified in a spectrophotometer (SpectraMax M5, Molecular Devices) by measuring 
absorbance of visible light at 405nm.  Raw absorbance values were obtained in software 
platform Softmax 6.4 (Molecular Devices) and interpolated along the standard calibration curve 
for conversion into PrPC concentration values. 
 
Figure 4.2. PrPC ELISA calibration curve.  Representative plot of pure recombinant human 
PrPC serial standards (0.625—20ng/mL) assayed in triplicate using a modified commercial 
ELISA kit.  Optical density values read at 405nm wavelength were obtained and plotted using 
Microsoft Excel.  Linear regression equation y=0.0514x – 0.0026 where y=OD and 
x=concentration is used to interpolate the latter when absorbance values (y) are obtained. 
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Figure 4.3. PrPC ELISA Diagram. (1) Well-embedded monoclonal antibody binds to the 144-
153 residue segment of PrPC. (2) AChE-conjugated monoclonal antibody binds to the N-terminal 
OR at residues 51-90. (3) Ellman’s reagent with substrate is added to produce yellow color in 
solution proportional to the amount of bound AChE-conjugated antibodies, and thus captured 
PrPC. 
 
 
 
4.5. Western Blotting 
 Western blotting was performed as previously described (Pham, et al. 2014).  Protein 
concentration of plasma samples was determined using the Bio-Rad DC assay and 30µg protein 
per well was loaded into 15% acrylamide gels for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  Protein was then transferred onto polyvinylidene fluoride (PVDF) 
membrane (FluoroTrans, Pall Life Sciences) at 100V for 1 hour.  Membranes were blocked in 
5% BSA in PBS-Tween 20 (0.1%) at RT for 1 hour.  Primary antibodies used for 
immunoblotting are as follows: PrPC (Santa Cruz sc-7693, 1:500), GFAP (Santa Cruz sc-6170, 
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1:500), ADAM10 (Abcam ab84595, 1:1000), Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH; Abcam ab9484, 1:1000), and actin (Santa Cruz sc-1616, 1:500).  Primary antibody 
incubation was performed either at RT for 1-2 hours or at 4°C O/N.  Following stringent washing 
and secondary antibody incubation steps, membranes were exposed to enhanced 
chemiluminescence (ECL) reagent (Amersham #45000875) and exposed to X-ray film.  Protein 
bands of interest were analyzed using NIH ImageJ software and normalized to that of the actin 
loading control in each sample lane.   
 
4.6. Statistical Analysis 
Statistical analysis for all data was performed using software platforms IBM Statistical 
Package for the Social Sciences (SPSS) 21 and Graphpad Prism 5.  All non-parametric statistical 
methods for analyses of plasma PrPC in blast-exposed rats is discussed below in section 5.1.  
Immunohistochemical comparison of relative fluorescence of targeted proteins in stained 
hippocampal sections was performed using student's T-test (see section 5.2).  Comparison of 
plasma PrPC concentration in restraint, whiplash, and net groups was performed using one-way 
analysis of variance (ANOVA) of results distribution, and post-hoc Dunnett’s multiple 
comparison test for significant pairings of blast groups and control (see section 5.1 and 5.2).  
Immunoblotting comparison of target proteins was also analyzed using one-way ANOVA and 
post-hoc Dunnett’s multiple comparison test for blast groups against control (see section 5.3). 
For sports concussion pilot experiments, T-test was performed for plasma PrPC mean value 
comparison of the following pairings: male vs. female, athletes vs. non-athletes, and post-TBI vs. 
baseline or combined athletes and non-athletes (see section 6.1).  One-way ANOVA was used to 
determine whether there is significant variation of mean PrPC concentration among different age 
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groups.  Immunoblotting comparison of target proteins in human samples was performed using 
T-test (see section 6.2).  For calculation of the reference interval (RI) of children’s plasma PrPC 
concentration as well as corresponding 90% CIs, non-parametric methods were used to establish 
the 95th percentile (see section 6.3).  T-test was performed for comparison between mean 
concentration values between genders.  Scatterplot and linear regression analysis was performed 
for trend determination between PrPC concentration and age progression.  Results were 
considered statistically significant when p ≤ 0.05. 
Table 4.1. Chemical and biological reagents, equipment and supplies 
Materials, Chemicals, and Biological Reagents Supplier 
Actin I19 sc1616 goat polyclonal antibody Santa Cruz 
ADAM10 ab84595 rabbit polyclonal antibody Abcam 
Alexa Fluor 488 Z25002 green mouse IgG1 labelling dye Life Technologies 
Alexa Fluor 594 Z25307 red rabbit IgG labelling dye Life Technologies 
Bovine Serum Albumin Sigma Aldrich 
Cryotome Shandon Life Sciences 
DAPI D1306 nuclear dye Life Technologies 
DC Protein assay #500-0113/-0114 Bio-Rad 
ECL Amersham #45000875 VWR 
Formaldehyde BDH0500-4LP VWR 
GAPDH ab9484 mouse monoclonal antibody Abcam 
Gelvatol (polyvinyl alcohol) #341584 Sigma Aldrich 
GFAP #18-0063 rabbit polyclonal antibody Life Technologies 
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GFAP C19 sc-6170 goat polyclonal antibody Santa Cruz 
Tissue-Tek Optimal Cutting Temperature (OCT) Compound VWR 
Tissue-Tek Cyromold VWR 
NFH SMI 32 mouse monoclonal antibody Cedarlane 
p-NFH SMI 31 mouse monoclonal antibody Cedarlane 
PBS Produced in lab 
PrPC C20 sc-7693 goat polyclonal antibody Santa Cruz 
PrPC ELISA A05201 Cedarlane 
PrPC recombinant mouse protein PrP-RPA0101S Prionatis 
PVDF Fluor Trans VWR 
Quorum WaveFX-X1 confocal microscope Quorum Technologies 
Spectramax M5 spectrophotometer Molecular Devices VWR 
Tris-Cl Produced in lab 
Triton X100 T8787 Sigma Aldrich 
Vacutainer K2EDTA #367841 Fisherbrand 
Vacutainer PST #367962 Fisherbrand 
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Section 5. Blast Exposure Results 
5.1. 
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5.2. Neuronal Dysregulation following Blast 
To show the presence of neuronal damage, immunohistochemical fluorescence staining 
was performed by Dr. Yushan Wang (DRDC) on neurofilament heavy chain (NFH) and GFAP.  
Neurofilaments are CNS-specific structural components of neurons that determine size and 
shape, and are also very abundant in axons as they are involved in maintaining axonal size, 
caliber, and nerve impulse conduction (Yuan, et al. 2012).  In various disease or neurological 
states involving neuronal and axonal degeneration or injury, including TBI, there is 
hyperphosphorylation of NFH (pNFH) (Shaw, et al. 2005).  Similarly, GFAP is also upregulated 
within astrocytes following neuronal injury and axonal denervation due to TBI (Burbach, et al. 
2004).  To show that blast exposure from 15-30 PSI is sufficient to cause neuronal injury, 
coronal brain sections containing the hippocampus, ipsilateral to the side of blast exposure, were 
prepared and stained for NFH (both normal and phosphorylated forms) and GFAP using 
fluorescent immunohistochemical techniques.  pNFH was indeed increased in blast exposed 
sections just over two-fold in the CA1 and dentate gyrus section of the hippocampus compared 
to sham controls (see figures 5.1 and 5.2).  Conversely, immunoreactivity to non-
phosphorylated NFH within these regions was not significantly different (see figure 5.3 and 
5.4).  Furthermore, GFAP staining also showed no upregulation in either hippocampal region 
(see figure 5.3 and 5.4).  This remains in line with previous findings showing that GFAP may 
not be robustly changed following mTBI in sports, which is very similar to bTBI (Neselius, et al. 
2012; Zetterberg, et al. 2006).  It is also possible that GFAP upregulation may not have occurred 
at 24 hours following injury; further testing  
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Figure 5.1. Immunofluorescence of pNFH-GFAP-DAPI in CA1.  One day following blast 
exposure (25 PSI; n=4) there is increased pNFH (red) in the CA1 region of the ipsilateral 
hippocampus by 2.18 fold compared to sham controls (0 PSI; n=4).  T-test shows that relative 
pNFH immunofluorescence intensity is significantly higher in blast (218.0 ± 57.0%) compared 
with normalized controls (100.0 ± 9.3%) (p<0.001). 
 
 
 
 
 
 
Relative fluorescence intensity of p-NFH in the CA1 region 
of ipsilateral hippocampus in rats exposed to 25 PSI blast 
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Figure 5.2. Immunofluorescence of pNFH-GFAP-DAPI in DG.  One day following blast 
exposure (25 PSI; n=4) there is increased pNFH (red) in the dentate gyrus area of the ipsilateral 
hippocampus by 2.2 fold compared to sham controls (0 PSI; n=4).  T-test shows that relative 
pNFH immunofluorescence intensity is significantly higher in blast (220.0 ± 40.5%) compared 
with normalized control (100 ± 9.5%) (p<0.001).  
 
  
  
Relative fluorescence intensity of p-NFH in the Dentate Gyrus 
area of ipsilateral hippocampus in rats exposed to 25 PSI blast 
 
 
58 
 
Figure 5.3. Immunofluorescence of NFH-GFAP-DAPI in CA1.  One day following blast 
exposure (25 PSI; n=4) there is no change in NFH (red) and GFAP (green) in the CA1 region of 
the ipsilateral hippocampus compared to sham controls (0 PSI; n=4).  T-test shows that relative 
NFH immunofluorescence is not significantly different in blast (87.0 ± 3.8%) compared with 
normalized control (100.0 ± 10.8%) (p>0.05).  Similarly, relative GFAP immunofluorescence is 
not significantly different in blast (99.0 ± 3.3%) compared with normalized control (100.0 ± 
7.8%) (p>0.05). 
 
  
  
Relative fluorescence intensity of NFH in the CA1 region of 
ipsilateral hippocampus in rats exposed to 25 PSI blast 
 
Relative fluorescence intensity of GFAP in the CA1 region of 
ipsilateral hippocampus in rats exposed to 25 PSI blast 
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Figure 5.4. Immunofluorescence of NFH-GFAP-DAPI in DG.  One day following blast 
exposure (25 PSI; n=4) there is no change in NFH (red) and GFAP (green) in the dentate gyrus 
area of the ipsilateral hippocampus compared to sham controls (0 PSI; n=4).  T-test shows 
relative NFH immunofluorescence intensity is not significantly different in blast (100.5 ± 5.5%) 
compared with normalized control (100.0 ± 8.0%) (p>0.05).  Similarly, relative GFAP 
immunofluorescence is not significantly different in blast (96.5 ± 1.3%) compared with 
normalized control (100.0 ± 7.7%) (p>0.05).  
 
 
  
Relative fluorescence intensity of NFH in the Dentate Gyrus  
area of ipsilateral hippocampus in rats exposed to 25 PSI blast 
 
Relative fluorescence intensity of GFAP in the Dentate Gyrus  
area of ipsilateral hippocampus in rats exposed to 25 PSI blast 
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5.3. Plasma PrPC Results. 
5.3.1. Multiple Conditions Comparison 
As shown in published work above, (see Section 5.1) pooled blast group data did not 
show normal distribution and non-parametric methods were used.  One-way ANOVA showed 
that different blast intensity exposure data sets differed significantly in distribution from restraint 
and whiplash, but not in net (see Figure 5.5).  Post-hoc Dunnett’s multiple comparison test for 
restraint group results shows that 15, 20, and 25 PSI were indeed significantly different than 
controls, but not for 30 PSI.  Post-hoc comparison of whiplash group results show that only 20 
PSI was significantly different than control.  And post-hoc comparison of net group results 
showed no significantly different pairing against control.  For results summary of plasma PrPC 
concentrations see Table 5.1. 
 
5.3.2. Long-term plasma PrPC time course 
 Comparison of plasma PrPC up to four weeks following blast exposure was also 
performed to determine the long-term change in plasma protein concentration (see Figure 5.5).  
Plasma samples were collected from restraint group S-D rats exposed to 25 PSI at different time 
points following exposure between 1-28 days.  Samples were not serially collected from the 
same animals over time, but instead were collected through decapitation for different sets of 
animals at each time point.  Kruskal-Wallis ANOVA shows that plasma PrPC is significantly 
elevated compared to sham controls 1 day after exposure.  PrPC remains slightly elevated up to 
one week, but returns to control levels by two weeks and beyond 
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5.3.3 Western Blotting of TBI biomarkers 
Western blot analysis for animals in restraint showed a marked increase in 
immunoreactivity (IR) for protein bands of PrPC, ADAM10, and ApoE at higher blast 
magnitudes at 25 and 30 PSI compared to sham controls (see Figure 5.7).  PrPC IR showed a 
blast intensity-dependent increase trend in all blast groups, but was only statistically significant 
to controls at higher intensities.  Immunoblotting for whiplash group shows that PrPC IR is 
similarly increased in plasma following blast exposure (see Figure 5.8).  ADAM10 and ApoE 
were also increased in whiplash group with increasing intensity, but not to the same degree as in 
restraint group animals.  Net group showed a slight upward trend in protein IR for all markers, 
but none were significantly elevated compared to controls (see Figure 5.9). 
 
Table 5.1. PrPC ELISA Results Summary 
 Plasma PrPC Concentration (ng/mL) 
Group PSI n Mean ± SD Median Range 
Sham 
Controls 
0 19 2.46 ± 0.63 2.66 0.67—3.35 
Restraint 15 7 3.74 ± 0.89 3.99 2.10—4.67 
20 7 4.27 ± 0.69 4.47 3.27—5.34 
25 12 4.18 ± 0.63 4.26 3.06—5.37 
30 7 3.54 ± 0.79 3.25 2.68—4.84 
Whiplash 15 2 3.21 ± 0.51 3.32 2.96—3.70 
20 3 4.10 ± 0.33 4.09 3.78—4.10 
25 3 3.17 ± 0.09 3.17 3.09—3.26 
30 7 3.13 ± 0.73 2.92 2.53—3.94 
Net 15 3 3.11 ± 0.20 3.17 2.89—3.28 
20 3 2.54 ± 0.18 2.58 2.35—2.71 
25 3 2.34 ± 0.30 2.17 2.16—2.69 
30 4 3.09 ± 0.54 3.29 2.30—3.48 
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Figure 5.5. Comparison of plasma PrPC in blast groups.  One-way ANOVA of plasma PrPC 
from different blast intensity exposed groups showed results were not equally distributed for 
restraint (p<0.0001) and whiplash (p=0.0013) groups, but not significant in net (p=0.1374).  
Post-hoc Dunnett’s multiple comparison test of blast groups vs control for restraint group is as 
follows: 15 PSI (p<0.001), 20 PSI (p<0.001), 25 PSI (p<0.001), and 30 PSI (p<0.01).  Post-hoc 
Dunnett’s multiple comparison test of blast groups vs control for whiplash group showed only 
20 PSI groups results were significantly different from control (p<0.001).  Post-hoc Dunnett’s 
multiple comparison test of blast groups vs control for net group showed that none of the groups 
were significantly different compared to control (p>0.05).  Note: see Table 5.1 for concentration 
values. 
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Figure 5.6. Long-term plasma PrPC comparison.  One-way ANOVA found that plasma PrPC 
concentration in 25 PSI blast exposed animals at different time points was significantly different 
in distribution compared to non-blast exposed controls (p<0.0001).  Post-hoc Dunnett’s multiple 
comparison test of plasma PrPC at different time points are as follows: 1 day (n=12, mean 4.18 ± 
0.63 ng/mL; p<0.001), 4 days (n=3, mean 3.54 ± 0.38 ng/mL; p<0.05), 7 days (n=4, mean 2.97 ± 
0.47 ng/mL; NS), 14 days (n=4, mean 2.56 ± 0.87 ng/mL; NS), 28 days (n=3, mean 2.39 ± 
0.66Gr ng/mL; NS), and control (n=19, mean 2.46 ± 0.63 ng/mL). 
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Figure 5.7. Restraint western blotting. One-way ANOVA found that mean IR of target 
proteins in blast exposed groups was significantly different relative to control for PrPC (p<0.05), 
ADAM10 (p<0.001), and ApoE (p<0.01).  Post-hoc Dunnett’s multiple comparison of blast 
groups against control for PrPC IR are as follows: 0 PSI (n=5, mean 1.00 ± 0.79 fold), 15 PSI 
(n=4, mean 1.78 ± 0.42 fold), 20 PSI (n=4, mean 1.52 ± 0.48 fold), 25 PSI (n=4, mean 2.25 ± 
0.45 fold; p<0.05), and 30 PSI (n=4, mean 2.42 ± 1.78 fold; p<0.05).  Post-hoc comparison of 
ADAM10 IR are as follows: 0 PSI (n=5, mean 1.00 ± 0.71 fold), 15 PSI (n=4, mean 1.32 ± 0.57 
fold), 20 PSI (n=4, mean 1.59 ± 0.72 fold), 25 PSI (n=4, mean 2.79 ± 0.59 fold; p<0.01), and 30 
PSI (n=4, mean 3.77 ± 0.85 fold; p<0.001).  Post-hoc comparison of ApoE are as follows: 0 PSI 
(n=5, mean 1.00 ± 0.03 fold), 15 PSI (n=4, mean 1.88 ± 0.63 fold), 20 PSI (n=4, mean 1.39 ± 
0.19 fold), 25 PSI (n=4, mean 3.03 ± 1.23 fold), and 30 PSI (n=4, mean 5.06 ± 1.42 fold; 
p<0.01).  Note: asterisks designate significance compared to corresponding control column. 
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Figure 5.8. Whiplash western blotting.  One-way ANOVA found that mean IR of PrPC in blast 
exposed groups was significantly different relative to control (p<0.01), but was not significant 
for ADAM10 (p>0.05), and ApoE (p=0.0502).  Post-hoc Dunnett’s multiple comparison of blast 
groups against control for PrPC IR are as follows: 0 PSI (n=5, mean 1.00 ± 0.79 fold), 15 PSI 
(n=2, mean 2.14 ± 1.32 fold), 20 PSI (n=3, mean 2.64 ± 1.17 fold), 25 PSI (n=3, mean 3.40 ± 
0.76 fold; p<0.01), and 30 PSI (n=3, mean 3.14 ± 1.04 fold; p<0.01).  Post-hoc comparison of 
ADAM10 IR are as follows: 0 PSI (n=5, mean 1.00 ± 0.71 fold), 15 PSI (n=2, mean 1.51 ± 0.43 
fold), 20 PSI (n=3, mean 1.59 ± 0.32 fold), 25 PSI (n=3, mean 1.89 ± 0.04 fold), and 30 PSI 
(n=3, mean 2.25 ± 0.07 fold; p<0.05).  Post-hoc comparison of ApoE are as follows: 0 PSI (n=3, 
mean 1.00 ± 0.81 fold), 15 PSI (n=2, mean 1.71 ± 0.28 fold), 20 PSI (n=3, mean 2.04 ± 0.60 
fold), 25 PSI (n=3, mean 1.80 ± 0.20 fold), and 30 PSI (n=3, mean 2.62 ± 0.48 fold; p<0.05).  
Note: asterisks designate significance compared to corresponding control column. 
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Figure 5.9. Net western blotting.  One-way ANOVA found that mean IR of target proteins in 
blast exposed groups was not significantly different relative to control for PrPC, Adam10, and 
ApoE (p>0.05).  Post-hoc Dunnett’s multiple comparison of blast groups against control for PrPC 
IR are as follows: 0 PSI (n=5, mean 1.00 ± 0.79 fold), 15 PSI (n=3, mean 1.46 ± 0.45 fold), 20 
PSI (n=3, mean 1.75 ± 0.67 fold), 25 PSI (n=3, mean 1.45 ± 0.28 fold), and 30 PSI (n=3, mean 
0.99 ± 0.59 fold).  Post-hoc comparison of ADAM10 IR are as follows: 0 PSI (n=5, mean 1.00 ± 
0.71 fold), 15 PSI (n=3, mean 1.39 ± 0.25 fold), 20 PSI (n=3, mean 0.93 ± 0.44 fold), 25 PSI 
(n=3, mean 1.09 ± 0.65 fold), and 30 PSI (n=3, mean 1.04 ± 0.69 fold).  Post-hoc comparison of 
ApoE are as follows: 0 PSI 0 PSI (n=3, mean 1.00 ± 0.73 fold), 15 PSI (n=3, mean 1.44 ± 1.16 
fold), 20 PSI (n=3, mean 1.14 ± 0.49 fold), 25 PSI (n=3, mean 1.17 ± 0.84 fold), and 30 PSI 
(n=3, mean 1.31 ± 0.81 fold).  Note: asterisks designate significance compared to corresponding 
control column. 
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Section 6. Human Study Results 
6.1. Establishing normal plasma PrPC concentration in Healthy Adults 
In order to investigate the possibility that the plasma level of PrPC rises following mTBI, 
normal soluble PrPC levels were first measured in  the general population aged 18 years and over 
(mostly U of S students) without significant confounds due to illness, health condition, or 
significant head injury within the past six months.  T-test comparison between male vs. female 
results showed no significant difference in mean concentration of plasma PrPC, although female 
concentration was slightly higher (see Figure 6.1).  Additionally, we found a slight significant 
difference in mean plasma PrPC between off season athletes’ baselines vs. normal non-athlete 
students (see Figure 6.1).  
Furthermore, aggregate results were separated into five age groups to determine any 
significant difference in plasma PrPC across different age brackets (see Figure 6.2).  One-way 
ANOVA for determining variation between mean plasma PrPC concentration across age groups 
showed no significant difference.  
  
6.2. Plasma soluble PrPC concentration increases in Concussed Athletes  
During the 2013-2014 season, the Huskies Athletic teams had 4 female and 2 male 
participants within the study who had suffered injuries causing concussion while engaging in 
various sports including Canadian football, ice hockey, basketball and wrestling.  Initial signs 
and symptoms following injury were evaluated for the six athletes along a scale using the 
SCAT3 criteria by teams’ doctors and physical therapists (see Table 6.1).  The SCAT3 criteria is 
a combination of the GCS, cognitive ability tests, and self-reporting of symptoms that help 
determine the degree of injury.  Individuals who identify themselves as having a symptom such 
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as dizziness, confusion, or being nauseous score these symptoms from a scale of 1-6 depending 
on increasing severity.  For almost all incidents, the injuries sustained by the athletes involved a 
significant blow to the head and/or included rapid whiplash acceleration of the head along the 
neck.  Depending on access and appropriate convenience to the concussed athletes, their blood 
samples were collected within 24hrs to 7 days post-mTBI.  T-test comparison of mean plasma 
PrPC in post-concussion samples was found to be significantly higher than levels in baseline 
samples collected during the offseason and against combined baselines with the normal 
population (see Figure 6.3.A).  Of the 76 baseline samples collected from athlete participants 
during the offseason, only three individuals sustained a concussion during the season to allow 
pre- and post-TBI comparison (see Figure 6.3.B).  Paired t-test comparison shows there was no 
significant difference between the three sets of pre- and post-TBI PrPC values, although our data 
showed an increasing trend.  For participant description and plasma PrPC results summary, see 
Table 6.2. 
 
6.2.1. Western blotting of human plasma TBI biomarkers 
 Comparative western blotting was performed on plasma samples from injured athletes 
and age- and gender- matched controls.  T-test comparison of IR for target proteins PrPC, 
ADAM10, and 14-3-3 were increased in post-concussion samples compared to combined 
baseline and normal population samples, but only PrPC and 14-3-3 were considered significant.  
Note: two of the post-TBI samples were excluded for Western blotting because of the prolonged 
period between injury and collection (seven days). 
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Figure 6.1. Group comparison of plasma PrPC.  Two-tailed unpaired student’s t-test shows no 
significant difference between male (n=54; 1.63 ng/mL ± 0.10 SEM) and female (n=49; 1.79 
ng/mL ± 0.10 SEM) (p>0.05).  T test of athletes (n=76, 1.59 ng/mL ± 0.07 SEM) vs. the normal 
non-athlete population (n=27; 2.02 ng/mL ± 0.15 SEM) shows significant difference between 
mean PrPC concentrations (p<0.01). 
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Figure 6.2. Comparison of plasma PrPC with age.   One-way ANOVA of PrPC concentrations 
for different age groups shows there is no significant difference between mean concentrations for 
subjects  between the ages of 18-20 (n=51; 1.66 ng/mL ± 0.68 SD), 21-33 (n=33; 1.61 ng/L ±  
0.58 SD), 24-26 (n=14; 1.89 ng/mL ± 0.78 SD), 27-29 (n=4; 2.13 ng/mL ± 0.51 SD), and those 
30 and over (n=9; 1.73 ng/mL ±  0.90 SD) (p>0.05).  
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Table 6.1. Description of participants’ head injury 
#ID Method of Injury Initial Signs & Symptoms  
LOC Balance Cognitive Symptom Scale 
(#symptoms/total 
score) 
Time from 
Injury to 
Collection 
HMF27 Helmet to helmet contact No Yes Yes 21/81 1 day 
HMF28 Unknown No No No 16/46 5 days 
HFB15 Elbow to head No No Yes 14/39 6 days 
HFH13 Collision with player head 
on but no head contact, 
whiplash 
No Yes No 6/13 2 days 
HFW1 Punch to face No No No 12/23 7 days 
HFW2 Knee to temple, punch to 
head 
No Yes No 19/71 7 days 
LOC = Loss of Consciousness 
 
Table 6.2. Plasma PrPC in adult humans 
Participant Summary  
 Age (years) PrPC Concentration (ng/mL) 
 n Mean ± SD Median  
 
Range 
 
Mean ± 
SEM 
Median  Range 
Non-Athlete 27 24.48 ± 2.99 24.00 18—30 2.02 ± 0.15 2.23 0.72—3.87 
Male 15 24.67 ± 1.76 24.00 22—29 2.12 ± 0.18 2.32 1.11—3.41 
Female 12 24.25 ± 4.14 23.50 18—30 1.89 ± 0.27 2.27  0.72—3.87 
 
Athlete 76 20.04 ± 1.84 20.00 18—26 1.59 ± 0.64 1.51 0.56—3.66 
Male 39 20.41 ± 1.92 20.00 18—24 1.44 ± 0.10 1.34 0.56—3.17 
Female 37 19.65 ± 1.70 19.00 18—26 1.75 ± 0.10 1.59  1.05—3.66 
 
Combined 103 21.20 ± 2.94 21.00 18—30 1.70 ± 0.07 1.55 0.56—3.87 
Male 54 21.59 ± 2.67  22.00 18—29 1.63 ± 0.10 1.40 0.56—3.41 
Female 49 20.78 ± 3.18 20.00 18—30 1.79 ± 0.10 1.62 0.72—3.87 
SD = Standard Deviation 
SEM = Standard Error of the Mean 
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Figure 6.3. Comparison between normal and post-concussion.  A) Two-tailed unpaired 
student’s t-test shows post-TBI PrPC concentrations (n=6; mean 2.96 ng/mL ± 0.37 SEM) are 
significantly elevated compared with either offseason athlete baseline concentration (n=76, mean 
1.59 ng/mL ± 0.07 SEM)(p<0.0001), or both athletes and non-athletes combined (n=103; mean 
1.70 ng/mL ± 0.07 SEM)(p<0.0001). B) Two-tailed paired t-test shows there was no significant 
difference between three sets of pre- and post-TBI PrPC values (p>0.05) 
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Figure 6.4. Concussed athlete western blotting.  T-test comparison of IR for target proteins 
between baseline/controls (rows 1-4) and post-TBI samples (rows 5-8) was significantly 
increased for PrPC (p<0.01) and 14-3-3 (p<0.001), but was not significant for ADAM10 
(p>0.05).   PrPC IR is increased in post-TBI samples (n=4, mean 2.26 ± 0.26 fold) compared with 
baseline/controls (n=8, mean 1.00 ± 0.21 fold).  14-3-3 IR is also increased in post-TBI samples 
(n=4, mean 2.64 ± 0.36 fold) (n=8, mean 1.00 ± 0.14 fold).  ADAM10 IR also showed an 
increase in post-TBI samples (n=4 mean 3.57 ± 1.34 fold), but was not significant in 
control/baseline (n=8, mean 1.00 ± 0.35 fold). 
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Section 7. Discussion 
7.1. General Discussion 
 Traumatic brain injury (TBI) is becoming a growing concern in society.  Not only does 
TBI affect the quality of life for individuals and those close to them, but it also poses legal 
ramifications with far reaching consequences in the context of sports and the military in regards to 
improper injury management.  The current standards of care all too often fail to properly diagnose 
those who have suffered a mild TBI, which is the most common injury in those admitted to 
emergency rooms.  Without proper diagnosis, those injured are at risk of developing debilitating 
symptoms without treatment as well as further injuring themselves that may have catastrophic 
outcomes.  A recent approach towards improving diagnosis of TBI has focused on evaluating 
protein concentrations in biological fluids that were indicative of injury.  In the case of TBI, these 
protein biomarkers are a result of damaged and degenerating tissue in the central nervous system 
(CNS) that allows these proteins to be released into the extracellular space.  Many proteins have 
been examined, but the search for feasible protein biomarkers is ongoing as there is no one 
definitive biomarker.  A protein that has been recently reported as a biomarker in various 
neurodegenerative conditions and diseases is the cellular prion protein (PrPC).  This protein is 
expressed abundantly in the CNS and is involved in various neuronal functions that collectively 
suggests it plays a neuroprotective role.  Thus begs the theory of whether PrPC, given its 
extracellular orientation, in neuronal cells is susceptible to TBI-induced damage that could lead to 
its release and subsequent pooling within the systemic circulation. 
   
 To explore this hypothesis of PrPC release following TBI, animal studies were conducted 
using a blast over pressure (BOP) exposure model on Sprague-Dawley (S-D) rats with 
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collaboration from the Defense Research and Development Canada (DRDC) center in Suffield, 
Alberta, Canada.  Using an advanced blast simulation tube (see section 4.1), adult S-D rats 
received head-only exposure to a single gas-driven primary blast wave at different intensities 
(15-30 PSI) with different head restraining conditions (restraint, whiplash, or net).  24 hours 
following exposure, animals were decapitated and exsanguinated for blood samples.  Removed 
brains were subjected to immunohistochemical analysis for cytoarchitecture changes indicative 
of TBI (see section 5.2), while blood samples underwent centrifugation for plasma fraction 
separation.  Plasma samples were analyzed using a modified commercial enzyme-linked 
immunosorbent assay kit (ELISA) for sensitive quantification of full-length soluble PrPC.  
Restraint condition samples were of particular interest because of the blast-only exposure 
component as opposed to whiplash and net groups, which involved acceleratory/decelerator 
forces from violent movement of the head and a semi-protective covering respectively.  Plasma 
PrPC from restraint group animals was indeed increased following blast exposure compared to 
sham controls (see section 5.1).  Although interestingly, plasma PrPC did not strictly increase in 
a blast intensity-dependent manner as concentrations seemingly taper off and even slightly 
decrease at higher intensities suggesting an “all-or-nothing” response mechanism.  Further study 
is required at lower blast intensity (<15 PSI) to deduce any mild intensity-dependent changes in 
plasma PrPC.  Combined analysis of plasma PrPC from restraint, whiplash, and net groups 
combined (see section 5.3.1) show that PrPC is significantly elevated following blast in restraint 
and whiplash groups, while net group results show an increased trend following blast, but was 
not significant.  Similar to restraint group, whiplash results also decreased slightly at higher blast 
intensity.  This may potentially be a result of limited sample size, especially in the case of 
whiplash.  But it may also suggest increased PrPC uptake in the brain in response to more severe 
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damage from higher blast intensities.  Such a response has been suggested in previous reports in 
light of PrPC’s involvement in important neuronal functions and neuroprotective qualities 
(Banks, et al. 2009; Carnini, et al. 2010).  The lack of significant increase in plasma PrPC for net 
group suggests that the head covering mitigated some of the blast exposure as evident by the 
slightly elevated levels.  Time course profiling of plasma PrPC over four weeks was also 
performed for restraint group animals exposed to 25 PSI.  PrPC was significantly elevated after 
one day, and proceeded to normalize to near control levels by one week, and then returned to 
control levels by two weeks and beyond (see section 5.3.2).  These results suggest that PrPC 
release remains elevated within the week, likely due to increased expression in the brain in 
response to secondary injury mechanisms and/or neuroinflammatory mediators.  Potential means 
of prolonged PrPC release that have previously been associated with TBI include adaptive 
responses to increased neurotoxicity and oxidative stress, inflammatory CCL2-mediatd release, 
upregulated ADAM10 sheddase activity, and possibly microvesicular exosome release 
(Altmeppen, et al. 2011; Brown, et al. 1997b; Cho, et al. 2013; Fevrier, et al. 2004; Graner, et al. 
2013; Roberts, et al. 2010; Semple, et al. 2010; Wang, et al. 2012; Warren, et al. 2012).  
Furthermore, it has previously been reported that following blast exposure Prnp is upregulated 
within the brain, but for however long and to what degree requires further investigation  
(Kochanek, et al. 2013).  Future study is needed to examine the acute release of plasma PrPC and 
determine whether there is a peak in PrPC concentration within 24 hours of blast exposure.   
  
 Western blot analysis further verified that PrPC is increased within the plasma following 
blast in a manner similar to ELISA results.  As previously reported, ADAM10 is upregulated 
following TBI and can also be secreted into the extracellular space within exosomes where it 
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actively cleaves cell surface proteins (Stoeck, et al. 2006; Warren, et al. 2012).  Combined with 
increased BBB permeability following TBI, it is possible that soluble ADAM10-containing 
exosomes are able to cross into the bloodstream.  Moreover, ADAM10 may continue to shed 
surface proteins such as PrPC that are also packaged during vesicular formation from the plasma 
membrane.  Future study using different region-specific antibodies for PrPC is needed to 
determine the degree of fractionation following TBI, which may be indicative of increased 
ADAM10 activity and/or reactive oxygen species.  Another well studied biomarker in TBI is 
apolipoprotein E (ApoE).  ApoE is a plasma lipid carrier produced by astrocytes and is abundant 
within the brain serving various functions such as neuronal maintenance, repair, growth, and 
synaptic plasticity (Houlden and Greenwood 2006).  Following TBI, ApoE levels within the 
brain increase as it plays a role in transporting lipids to damaged neurons in aiding repair.  
Similarly, in a study examining temporal lobe epilepsy, plasma ApoE was shown to dramatically 
increase compared to controls (Kumar, et al. 2006).  Typically, ApoE is investigated in the 
context of TBI for its ε4 isoform, which is believed to be a risk factor indicator for poor CNS 
response following TBI (Samatovicz 2000).  However, Western blotting was performed using 
primary antibody specific to a region within the protein’s C-terminal allowing binding of all 
ApoE isoforms as this protein is only polymorphic within its lipid binding N-terminal.  Thus, in 
addition to PrPC, Western blotting shows ADAM10 and ApoE IR is also increased following 
blast exposure, more so in restraint group than whiplash.   And as expected, IR for markers in net 
group were not significantly elevated following blast, likely as a result of the protective head 
covering mitigating imposed damage.  It must be noted that for whiplash 15 PSI group, BOP 
animal experiments show that PrPC can be used as a marker for bTBI in animals, which begs the 
question of whether the protein can be used as a marker for mTBI in sports-related concussion. 
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 To address this query, blood plasma was collected from the normal healthy adult 
population (age 18-30 years old) of the University of Saskatchewan (U of S) student body in 
addition to concussed student athletes from the U of S Huskies athletic teams for quantification 
of PrPC using ELISA.  Previous reports of plasma PrPC concentration are conflicting nor were 
they sampled from an appropriate age group that could correspond with student athlete 
participants (Breitling, et al. 2012; Mitsios, et al. 2007; Roberts, et al. 2010; Volkel, et al. 2001).  
Thus, it was necessary to sample a sufficient number of participants to establish normal values.  
Controls consisted of non-athlete participants from the U of S in addition to baseline samples 
collected from athletes during the offseason before regular contact.  Significant age and gender 
variation was not observed in normal plasma PrPC results, which for our purposes makes PrPC an 
ideal biomarker within the general population (see section 6.1).  Female values were slightly 
higher than males though not significantly, which is in line with previous reports of a non-
significant trend with gender (Breitling, et al. 2012).  Interestingly, lower soluble PrPC 
concentration was observed among offseason athlete baseline values as compared with non-
athlete students.  A possible reasoning for this is that collegiate level athletes are well 
conditioned physically and have lower blood pressure than the general population.  Since PrPC is 
also expressed on endothelial cell lining (Simak, et al. 2012), those with higher blood pressure 
would release more PrPC into the blood as was shown in a hypertensive population (Breitling, et 
al. 2012).  Another example of differing protein levels related to physical fitness was recently 
reported by Bazarian and coworkers in serum levels of ApoA1 and S100B autoantibody titer 
between off-season athletes and their controls (Bazarian, et al. 2014).  Further study is needed to 
determine whether plasma PrPC levels is affected by an individual’s fitness level.  Analysis of 
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post-mTBI/concussion samples show a significant rise in plasma PrPC compared with combined 
baseline and non-athlete samples (see section 6.2).    However, comparison of corresponding 
pre- and post-TBI values did not show significant difference despite an upward trend in the 
latter.  It is noteworthy that of the six post-TBI samples, only three had a paired baseline sample 
to compare against, and these pairs do show a slight increase in PrPC concentration despite 
delayed periods in collection following injury (see table 6.1).  Extreme examples of this can be 
seen when comparing the trend for MF and FB samples.  The MF post-injury sample was 
collected shortly after injury (1 day) while the FB was collected much later (6 days) (see figure 
6.3-B).  It is likely that the lack of any appreciable elevation in PrPC within the FB samples is a 
result of this time latency.  Another factor to consider is that of all the injured athletes sampled, 
the MF participant had the highest number of self-reported symptoms (21) with high severity (81 
out of possible 126 symptom score) (see table 6.1).  Thus, higher injury severity may contribute 
towards higher plasma PrPC following injury in the MF participant.  Unfortunately, correlation 
analysis could not be performed in this study due to non-controlled sampling times following 
injury, but such considerations would strengthen the feasibility of PrPC as an ideal biomarker for 
TBI.  Further study is underway and has been broadened to include more serious injuries that are 
to be collected from patients admitted to the Royal University Hospital (RUH) emergency room.   
   
To further validate that plasma PrPC can be used as a biomarker for mTBI/concussion, 
Western blotting was performed for PrPC and other target proteins that have been previously 
reported as markers of TBI.  14-3-3 is a CNS-specific intracellular scaffolding protein expressed 
abundantly on neural and glial cells, and has been reported to be increased in the brain and CSF 
following mTBI (Arun, et al. 2013; Siman, et al. 2004).  Comparison of four post-TBI samples 
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against combined baseline and normal controls shows there is a significant increase in PrPC and 
14-3-3 (see figure 6.4).  ADAM10 was also increased but was not significant due to high 
variability from prolonged collection latency.  Further analysis with increased pre- and post-TBI 
pairings with more acute collection times is required to definitively rule on PrPC’s applicability 
for mTBI/concussion diagnosis. 
mTBI and bTBI are similar in that most cases present with sparse neurodegeneration and 
injuries are typically not accompanied by complications such as sleep apnea, seizures, or 
mortality.  The identification of surrogate protein biomarkers for determining acute brain 
damage, secondary brain injury, severity, as well as prognosis remains an active and relevant 
area of research.  Such biomarkers could be used to complement the current standard clinical 
tests for TBI identification, and facilitate hospital resource allocation and patient management. 
Sport-related mTBI and military-related bTBI are significant health concerns to athletes and 
military service-members respectively, as TBI poses a high risk of long-term consequences for 
individuals who fail to properly manage their injuries.  PrPC is abundantly expressed throughout 
the CNS.  PrPC’s cellular location and functions suggests it has various neuroprotective 
properties.  Previous reports have linked plasma PrPC levels as biomarkers of brain injury and 
neurodegeneration, but none have examined its applicability to TBI, which itself involves both 
acute and prolonged brain injury mechanisms and is highly associated with long-term 
neurodegenration.  The contents of this thesis submit that PrPC is indeed increased within the 
plasma following TBI using a BOP animal model and a small human pilot project.  If findings 
from previous reports apply, it is likely that PrPC is released in the acute period from damaged 
neurons and is subsequently upregulated in affected areas as a means of ameliorating TBI-
mediated dysregulation of signaling pathways and ion homeostasis.  Simultaneously, mediators 
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of secondary injury, upregulated cleavage enzymes, and persistent neurotoxic environment  
following TBI can contribute towards further release of PrPC from neurons.  Given the protein’s 
ability to traverse the BBB normally, it stands to reason that free PrPC can accrue even more 
within the periphery through a highly permeable BBB following TBI.  At this time it is not clear 
whether PrPC is a highly specific marker of TBI only; further study is required to examine the 
effects of polytrauma, which includes impact to the head and the body as most cases of TBI are 
never inclusive of head-only injuries.  However, the findings presented here present a promising 
addition to the large body of evidence comprising the complex pathology of TBI. 
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7.2. Future Research Goals 
 Determine the exact release mechanism of PrPC following TBI using in vitro cell 
culturing technique.  By using antibodies towards ADAM10, we can determine the 
contribution that ADAM10 may play towards PrPC cleavage following TBI by 
comparison with non-treated cultures.   
o Determie if TBI causes fractionation of PrPC by performing sequential Western 
blotting with antibodies targeting different epitotes of PrPC.  This is important as 
different fragments can have distinct physiological effects. 
 
 Determine whether the release of soluble PrPC following TBI is a neuroprotective 
phenomenon by using cultured primary neurons isolated from wild type, PrP-KO and 
Tg20 (overexpresses 20 time more PrPC) mice in an invitro set up similar to what 
mentioned above.  We can also use recombinant PrPC in culture media and monitor the 
outcome with different techniques including immunohistochemical analysis.  
Furthermore, treatment of PrPC-knockout cell cultures with various fragments of PrPC 
will determine functional regions associated with improved outcome to perhaps provide 
potential therapeutic targets, such as PrPC region-mimicking peptides, for acute treatment 
of TBI.  Protein complex immunoprecipitation will be performed on said PrPC fragments 
to determine binding complex formation with potential lipid raft receptors or signaling 
molecules. 
 
 Produce a single and repetive mTBI animal model using a weight drop injury method as 
previously developed (Marmarou, et al. 1994; Foda, et al., 1994).  Sampling of blood 
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samples during the acute period following injury to delineate whether PrPC 
concentrations peak within 24 hours.  Also, head-only, body-only, and combined impact 
trials will be performed to determine whether blows to the body significantly affect 
plasma PrPC levels given it’s ubiquitous expression. 
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